

ANNUAL STATEMENT

For the Year Ended December 31, 2019 of the Condition and Affairs of the

HMO Partners, Inc

NAIC Group Code 876, 876 (Current Period) (Prior Peri		y Code 95442	Employer's ID Number 71-0747497
Organized under the Laws of Arkansas		cile or Port of Entry Arkansas	Country of Domicile US
Licensed as Business Type Health Main		Is HMO Federally Qualified? Yes	·
Incorporated/Organized November 8,	•	Commenced Business January	
Statutory Home Office	320 West Capitol Little Rock	•	,,
Main Administrative Office	320 West Capitol Little Rock (Street and Number) (City or Tow	AR US 72203-8069 vn, State, Country and Zip Code)	501-221-1800 (Area Code) (Telephone Number)
Mail Address	320 West Capitol Little Rock (Street and Number or P. O. Box)	AR US 72203-8069 (City or Town, State, Country and Zip Code)	
Primary Location of Books and Records	601 S. Gaines Little Rock A (Street and Number) (City or Tow	AR US 72201 vn, State, Country and Zip Code)	501-378-2000 (Area Code) (Telephone Number)
Internet Web Site Address	healthadvantage-hmo.com		
Statutory Statement Contact	Scott Bradley Winter (Name)		501-399-3951 (Area Code) (Telephone Number) (Extension)
	sbwinter@arkbluecross.com (E-Mail Address)		501-378-3258 (Fax Number)
	OFFI	CERS	
Name 1. John Charles Glassford Jr. 3. Scott Bradley Winter	Title President/CEO Assistant Treasurer	Name 2. Gray Donald Dillard 4.	Title Treasurer/CFO
•	ОТ	HER	
Timothy Gerard Gauger #	Secretary	Troy Russell Wells #	Vice Chairman
Steven Aaron Spaulding	Chairman	·	
		OR TRUSTEES	
Lavanda Moore Gangluff APN Jo Calvin Eugene Kellogg Ch	urtis Edwin Barnett hn Charles Glassford Jr. narles Edgar Phillips MD oy Russell Wells	Brent William Beaulieu # Richard Loyd Gore DDS Tonya Renee Robertson	Gray Donald Dillard Matthew Ridgway Jones Steven Aaron Spaulding
State of Arkansas County of Pulaski			
The officers of this reporting entity being duly sustated above, all of the herein described assets	were the absolute property of the sai	d reporting entity, free and clear from any	liens or claims thereon, except as

stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC *Annual Statement Instructions* and *Accounting Practices and Procedures* manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

	(Signature)		(Signature)		(Signature)		
	John Charles Glassford Jr.		Gray Donald Dillard	Sci	Scott Bradley Winter		
	1. (Printed Name)		2. (Printed Name)	3	. (Printed Name)		
	President/CEO		Treasurer/CFO	A	ssistant Treasurer		
	(Title)		(Title)		(Title)		
Subscribed an	d sworn to before me		a. Is this an original filing?		Yes [X] No []	
This	day of	2020	b. If no 1. State the ame	endment number			
			2. Date filed		•		
			3. Number of pa	ages attached			
	•				•		

1				Current Year		Prior Year
6. Sonds (Scholar D) 5-100 (Scholar D) 6-100 (Scholar D) 6-20 (Scholar D) 2. Sonds (Scholar D) 2-1 Preferent stocks 6-20 (Scholar D) 6-20 (Scholar D) 2.1 Preferent stocks 8-20 (Scholar D) 6-20 (Scholar D) 3.1 Preferent stocks 9-20 (Scholar D) 6-20 (Scholar D) 3.1 Preferent stocks 9-20 (Scholar D) 9-20 (Scholar D) 4.1 Preparete stocks of the stock of Scholar D) 9-20 (Scholar D) 9-20 (Scholar D) 4.2 Preparete feel for the final position (Scholar D) 9-20 (Scholar D) 9-20 (Scholar D) 4.3 Preparete feel for the feel of Scholar D) 9-20 (Scholar D) 9-20 (Scholar D) 4.3 Preparete feel for the feel of Scholar D) 9-20 (Scholar D) 9-20 (Scholar D) 4.3 Preparete feel for the feel of Scholar D) 9-20 (Scholar D) 9-20 (Scholar D) 7. Detections (Scholar D) 9-20 (Scholar D) 9-20 (Scholar D) 8. Other (model asset) (Scholar D) 9-20 (Scholar D) 9-20 (Scholar D) 9. Souther (Scholar D) 9-20 (Scholar D) 9-20 (Scholar D) 10. Souther (Scholar D) 9-20 (Scholar D) 9-20 (Scholar D) 10. Souther (Scholar D) <t< th=""><th></th><th></th><th>1</th><th>_</th><th>Assets</th><th>4 Net</th></t<>			1	_	Assets	4 Net
2 Strong Streeture 17 2 1 Preferred stocks.			Assets	Assets	(Cols. 1 - 2)	Admitted Assets
2.1 Professed above.	1.	Bonds (Schedule D)	54,037,018		54,037,018	52,973,802
2 2 Common stacks 6,393,881 6,590,661 6,294,444	2.	Stocks (Schedule D):				
3. Mortgage tons on real estate (Schedule II): 3.1 First Ieer.		2.1 Preferred stocks			0	
3.1 First less.		2.2 Common stocks	6,993,681		6,993,681	6,204,484
2 2 10 tent than first less	3.	Mortgage loans on real estate (Schedule B):				
4. Real estate (Schedule A). 4. Propositios cocapida by the company (less 8 0 evaluations (Schedule A). 4. Propositios cocapida by the company (less 8 0 evaluations (Schedule A). 4. Propositios hald for the production of income (less 8 0 evaluations (Schedule A). 4. Propositios hald for the production of income (less 8 0 evaluations (Schedule A). 5. Cenh (8 3) 889 248 3. Schedule E-Part 1), control reconstruction (5 841725). 5. Cenh (8 3) 889 248 3. Schedule E-Part 1), control reconstruction (5 841725). 6. Cenh (8 3) 889 248 3. Schedule E-Part 1), control reconstruction (5 841725). 7. Denhatituse (Schedule B). 8. Chemin metabol assets (Schedule BA). 9. Denhatituse (Schedule BA). 9. Reconstruction (5 841725). 9. Schedule E-Part 2) and struction (6 841725). 9. Schedule E-Part 2) and struction		3.1 First liens			0	
4.1 Properties occupied by the company (less \$ 1 0 0		3.2 Other than first liens			0	
1- Perumbronosa	4.	Real estate (Schedule A):				
Second S					0	
5. Class (S. J. 3.88 82.45, Schodule E Part 1), soth equivalents (S					0	
Schedule C-Part 2) and stort stem investments (6647) 255. Storbule DA) 41,986,748 41,986,748 34,119,227		4.3 Properties held for sale (less \$0 encumbrances)			0	
7. Destratives (Schedule DB)	5.		41,986,748		41,986,748	34,119,227
8. Other invested assets (Schedule BA). 11,470,775	6.	Contract loans (including \$0 premium notes)			0	
9. Receivables for securities 10. Securities lemiting relievated collateral assets (Schedule DL) 10. Aggregate write-ins for invested assets 10. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	7.	Derivatives (Schedule DB)			0	
9. Receivables for securities 10. Securities lemiting relievated collateral assets (Schedule DL) 10. Aggregate write-ins for invested assets 10. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		,				
10 Securities landing reinvested collateral assats (Schedule DL)	9.	,				
11. Aggregate write-ins for invested assets (Lines 1 to 11)	10.					
12 Subtotals, cash and invested assets (Lines 1 to 11)	11.					
13. Title plants less \$						
14. Investment income due and accoued.						
15. Premiums and considerations:						
15.1 Uncollected premiums and agents' balances in the course of collection. 15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including 5						
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$) earned but unbilled premiums).	13.				0	
and not yet due (including \$0 earned but unbilled premiums)					0	
15.3 Accrued retrospective premiums (\$3.509,013) and contracts subject to redetermination (\$918,527). 4.427,540 68,174 4,393,366 3,360,120 16. Reinsurance:		, , , ,			0	
16.1 Amounts recoverable from reinsurers		15.3 Accrued retrospective premiums (\$3,509,013) and contracts subject to		68,174	4,359,366	3,360,120
16.2 Funds held by or deposited with reinsured companies	16.	Reinsurance:				
16.3 Other amounts receivable under reinsurance contracts		16.1 Amounts recoverable from reinsurers	319,555 .		319,555	1,730,951
17. Amounts receivable relating to uninsured plans		16.2 Funds held by or deposited with reinsured companies			0	
18.1 Current federal and foreign income tax recoverable and interest thereon 3,789,989 3,789,989 1,823,274 18.2 Net deferred tax asset. 1,247,568 1,247,568 .880,502 19. Guaranty funds receivable or on deposit.		16.3 Other amounts receivable under reinsurance contracts			0	
18.1 Current federal and foreign income tax recoverable and interest thereon 3,789,989 3,789,989 1,823,274 18.2 Net deferred tax asset. 1,247,568 1,247,568 .880,502 19. Guaranty funds receivable or on deposit.	17.	Amounts receivable relating to uninsured plans	18,590,216		18,590,216	11,921,302
18.2 Net deferred tax asset. 1,247,568 .880,502 19. Guaranty funds receivable or on deposit. .0						
19. Guaranty funds receivable or on deposit.	18.2	-				
20. Electronic data processing equipment and software.						
21. Furniture and equipment, including health care delivery assets (\$0)		·				
22. Net adjustment in assets and liabilities due to foreign exchange rates. 0 23. Receivables from parent, subsidiaries and affiliates. 0 24. Health care (\$5,611,271) and other amounts receivable. .7,523,750 1,912,480 .5,611,271 .4,685,976 25. Aggregate write-ins for other-than-invested assets. .1,393,043 .700,000 .693,043 .518,180 26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25). .152,218,628 2,680,654 .149,537,974 .128,331,714 27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts. .152,218,628 2,680,654 .149,537,974 .128,331,714 DETAILS OF WRITE-INS 1101. .0 .0						
23. Receivables from parent, subsidiaries and affiliates						
24. Health care (\$5,611,271) and other amounts receivable. 7,523,750 1,912,480 .5,611,271 .4,685,976 25. Aggregate write-ins for other-than-invested assets. 1,393,043 700,000 .693,043 .518,180 26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25). 152,218,628 2,680,654 .149,537,974 .128,331,714 27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts. 0 .0 .0 .0 .2,680,654 .149,537,974 .128,331,714 DETAILS OF WRITE-INS 1101. 0 .0 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td></td<>						
25. Aggregate write-ins for other-than-invested assets. 1,393,043 700,000 693,043 518,180 26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25). 152,218,628 2,680,654 149,537,974 128,331,714 27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts. 0 0 152,218,628 2,680,654 149,537,974 128,331,714 DETAILS OF WRITE-INS 1101. 0 0 0 0 1102. 0 0 0 0 1103. 0 0 0 0 0 1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above) 0 0 0 0 0 2501. Supplemental Savings Plan. 591,733 591,733 591,733 440,948 2502. Other Assets. 801,310 700,000 101,310 772,232 2503. 0		·				
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)						
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts.		Total assets excluding Separate Accounts, Segregated Accounts and Protected				
28. TOTAL (Lines 26 and 27)	27.					
DETAILS OF WRITE-INS						
1102 0 1103 0 1198. Summary of remaining write-ins for Line 11 from overflow page. 0 1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above). 0 2501. Supplemental Savings Plan. 591,733 2502. Other Assets. 801,310 2503. 0 2598. Summary of remaining write-ins for Line 25 from overflow page. 0 0 0 0 0 0 0 0 0		DETAILS O	F WRITE-INS		<u>'</u>	
1103 0 1198. Summary of remaining write-ins for Line 11 from overflow page. 0 0 0 0 1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above). 0 0 0 0 2501. Supplemental Savings Plan. 591,733 591,733 440,948 2502. Other Assets. 801,310 700,000 101,310 77,232 2503. 0 0 0 0 0 2598. Summary of remaining write-ins for Line 25 from overflow page. 0 0 0 0 0	1101.				0	
1198. Summary of remaining write-ins for Line 11 from overflow page. 0 0 0 0 1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above). 0 0 0 0 2501. Supplemental Savings Plan. 591,733 591,733 440,948 2502. Other Assets. 801,310 700,000 101,310 77,232 2503. 0 0 0 0 0 2598. Summary of remaining write-ins for Line 25 from overflow page. 0 0 0 0						
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above). 0						
2501. Supplemental Savings Plan. .591,733 .591,733 .440,948 2502. Other Assets. .801,310 .700,000 .101,310 .77,232 2503. .0 .0 .0 .0 .0 2598. Summary of remaining write-ins for Line 25 from overflow page. .0 .0 .0 .0 .0						
2502. Other Assets.						
2503.		• • • • • • • • • • • • • • • • • • • •				-,-
2598. Summary of remaining write-ins for Line 25 from overflow page			•	·	•	· ·
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)				0	0	0
	2599.	Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	1,393,043	700,000	693,043	518,180

Statement as of December 31, 2019 of the HMO Partners, Inc LIABILITIES, CAPITAL AND SURPLUS

	LIABILITIES, CAP		Current Period		Prior Year
		1 Covered	2 Uncovered	3 Total	4 Total
1.	Claims unpaid (less \$7,003,457 reinsurance ceded)				
2.	Accrued medical incentive pool and bonus amounts				
3.	Unpaid claims adjustment expenses				
4.	Aggregate health policy reserves, including the liability of \$0 for	,,,,,,		_,-,-	.,,
	medical loss ratio rebate per the Public Health Service Act	135,394		135,394	445,146
5.	Aggregate life policy reserves			0	
6.	Property/casualty unearned premium reserves				
7.	Aggregate health claim reserves			0	
8.	Premiums received in advance	3,134,917		3,134,917	3,442,031
9.	General expenses due or accrued	3,578,013		3,578,013	3,313,477
10.1	Current federal and foreign income tax payable and interest thereon (including \$0 on realized capital gains (losses))			0	
10.2	Net deferred tax liability			0	
11.	Ceded reinsurance premiums payable	118,407		118,407	174,157
12.	Amounts withheld or retained for the account of others	904,958		904,958	883,853
13.	Remittances and items not allocated	882,664		882,664	873,065
14.	Borrowed money (including \$0 current) and interest thereon \$0 (including \$0 current)			0	
15.	Amounts due to parent, subsidiaries and affiliates				
16.	Derivatives				
17.	Payable for securities				
18.	Payable for securities lending				
19.	Funds held under reinsurance treaties with (\$0 authorized reinsurers,				
	\$0 unauthorized reinsurers and \$0 certified reinsurers)				
	Reinsurance in unauthorized and certified (\$0) companies				
	Net adjustments in assets and liabilities due to foreign exchange rates				
	Liability for amounts held under uninsured plans			30,095,872	, ,
	Aggregate write-ins for other liabilities (including \$0 current)				
24.	Total liabilities (Lines 1 to 23)				
25.	Aggregate write-ins for special surplus funds				
26.	Common capital stock				
27.	Preferred capital stock				
28.	Gross paid in and contributed surplus				
29.	Surplus notes				
30.	Aggregate write-ins for other-than-special surplus funds				
31.	Unassigned funds (surplus)	XXX	XXX	62,883,939	66,212,781
32.	Less treasury stock at cost:				
	32.10.000 shares common (value included in Line 26 \$0)				
	32.20.000 shares preferred (value included in Line 27 \$0)				
	Total capital and surplus (Lines 25 to 31 minus Line 32)				
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	149,537,974	128,331,716
		S OF WRITE-INS			
	Summary of remaining write-ins for Line 23 from overflow page				
	Totals (Lines 2301 through 2303 plus 2398) (Line 23 above)				
	2020 ACA Insurer Fee estimate.				
	Summary of remaining write-ins for Line 25 from overflow page				
	Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)				
1	Totals (Lines 2501 tillough 2505 plus 2596) (Line 25 above)				
	Summary of remaining write-ins for Line 30 from overflow page				0
	Totals (Lines 3001 through 3003 plus 3098) (Line 30 above)				0
		2		0	

3

Statement as of December 31, 2019 of the HMO Partners, Inc STATEMENT OF REVENUE AND EXPENSES Current Year

		Currer		Prior Year	
		1 Uncovered	2 Total	3 Total	
1.	Member months	XXX	538,304	617,868	
2.	Net premium income (including \$0 non-health premium income)				
3.	Change in unearned premium reserves and reserve for rate credits				
4.	Fee-for-service (net of \$0 medical expenses)				
5.	Risk revenue				
6.	Aggregate write-ins for other health care related revenues				
7.	Aggregate write-ins for other non-health revenues Total revenues (Lines 2 to 7)				
8.		XXX	211,916,338	226,790,781	
	ital and Medical:				
9.	Hospital/medical benefits		154,916,074		
10.	Other professional services				
11.	Outside referrals		, ,	, ,	
12.	Emergency room and out-of-area		36,895,019	46,128,993	
13.	Prescription drugs				
14.	Aggregate write-ins for other hospital and medical	0	0	0	
15.	Incentive pool, withhold adjustments and bonus amounts		1,015,051	(6,298,424)	
16.	Subtotal (Lines 9 to 15)	0	256,950,293	279,108,208	
Less	:				
17.	Net reinsurance recoveries		78,110,142	88,173,795	
18.	Total hospital and medical (Lines 16 minus 17)	0	178,840,151	190,934,413	
19.	Non-health claims (net)				
20.	Claims adjustment expenses, including \$10,810,486 cost containment expenses				
21.	General administrative expenses.		23,992,818		
22.	Increase in reserves for life and accident and health contracts including \$0		20,032,010	27,010,001	
22.	increase in reserves for life only)				
23.	Total underwriting deductions (Lines 18 through 22)				
	Net underwriting gain or (loss) (Lines 8 minus 23)				
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)		2,441,466	2,030,478	
	Net realized capital gains or (losses) less capital gains tax of \$21,699				
26.			2.316.440	7.959.064	
27.	Net investment gains or (losses) (Lines 25 plus 26)	0	2,310,440	7,959,064	
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$0) (amount charged off \$0)]				
29.	Aggregate write-ins for other income or expenses	0	261,242	221,690	
30.	Net income or (loss) after capital gains tax and before all other federal income taxes				
	(Lines 24 plus 27 plus 28 plus 29)		,		
31.	Federal and foreign income taxes incurred				
32.	Net income (loss) (Lines 30 minus 31)	•	(897,500)	6,409,698	
	DETAILS OF WRIT				
	Summary of remaining write-ins for Line 6 from overflow page		0	0	
	Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)		0		
0703.		XXX			
0798.	Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0	
	Totals (Lines 0701 through 0703 plus 0798) (Line 7 above)		0	0	
	Summary of remaining write ins for Line 14 from overflow page				
	Summary of remaining write-ins for Line 14 from overflow page		0		
	Licensing fee income				
	Miscellaneous Income.		101,242		
2903.	WISCOLUTECTOS IIICOLUC		101,272	•	
	Summary of remaining write-ins for Line 29 from overflow page		0		
	Totals (Lines 2901 through 2903 plus 2998) (Line 29 above)		261,242	221,690	

Statement as of December 31, 2019 of the HMO Partners, Inc STATEMENT OF REVENUE AND EXPENSES (Continued)

	CAPITAL AND SURPLUS ACCOUNT	1 Current Year	2
	CAPITAL AND SURPLUS ACCOUNT		D: 1/
			Prior Year
	apital and surplus prior reporting period	68,141,933	67,535,434
34. N	et income or (loss) from Line 32	(897,500)	6,409,698
35. CI	hange in valuation basis of aggregate policy and claim reserves		
36. C	hange in net unrealized capital gains and (losses) less capital gains tax of \$0	2,563,494	(6,481,030)
37. CI	hange in net unrealized foreign exchange capital gain or (loss)		
38. C	hange in net deferred income tax	261,155	(363,104)
39. CI	hange in nonadmitted assets	(885,085)	1,713,661
40. C	hange in unauthorized and certified reinsurance		
41. C	hange in treasury stock		
42. C	hange in surplus notes		
43. C	umulative effect of changes in accounting principles		
44. Ca	apital changes:		
44	4.1 Paid in		
44	4.2 Transferred from surplus (Stock Dividend)		
44	4.3 Transferred to surplus		
45. Sı	urplus adjustments:		
45	5.1 Paid in		
45	5.2 Transferred to capital (Stock Dividend)		
45	5.3 Transferred from capital		
46. D	ividends to stockholders	(640,968)	(672,727)
47. Aç	ggregate write-ins for gains or (losses) in surplus	0	0
48. No	et change in capital and surplus (Lines 34 to 47)	401,096	606,499
49. C	apital and surplus end of reporting period (Line 33 plus 48)	68,543,028	68,141,933
	DETAILS OF WRITE-INS		
4701			
4702			
4703			
4798. Si	ummary of remaining write-ins for Line 47 from overflow page	0	0
4799. To	otals (Lines 4701 through 4703 plus 4798) (Line 47 above)	0	0

	1 Current Year	2 Prior Year
CASH FROM OPERATIONS	Current real	FIIOI Teal
Premiums collected net of reinsurance	210,498,515	226.689.541
2. Net investment income		2,301,750
3. Miscellaneous income		
4. Total (Lines 1 through 3)	213,027,213	228,991,291
Benefit and loss related payments	177,075,085	188,531,116
Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7. Commissions, expenses paid and aggregate write-ins for deductions	24,267,581	34,136,916
8. Dividends paid to policyholders		
9. Federal and foreign income taxes paid (recovered) net of \$0 tax on capital gains (losses)		2,500,001
10. Total (Lines 5 through 9)		225,168,032
11. Net cash from operations (Line 4 minus Line 10)	9,184,547	3,823,259
CASH FROM INVESTMENTS		
12. Proceeds from investments sold, matured or repaid:		
12.1 Bonds		25,727,750
12.2 Stocks		11,293,698
12.3 Mortgage loans		
12.4 Real estate		
12.5 Other invested assets	144,832	106,110
12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		(541
12.7 Miscellaneous proceeds		298,864
12.8 Total investment proceeds (Lines 12.1 to 12.7)	12,094,417	37,425,881
13. Cost of investments acquired (long-term only):		
13.1 Bonds	11,398,112	38,890,485
13.2 Stocks		208,097
13.3 Mortgage loans		
13.4 Real estate		
13.5 Other invested assets		10,150,082
13.6 Miscellaneous applications		
13.7 Total investments acquired (Lines 13.1 to 13.6)	13,735,648	49,248,664
14. Net increase (decrease) in contract loans and premium notes		
15. Net cash from investments (Line 12.8 minus Lines 13.7 minus Line 14)	(1,641,230)	(11,822,783
CASH FROM FINANCING AND MISCELLANEOUS SOURCES		
16. Cash provided (applied):		
16.1 Surplus notes, capital notes		
16.2 Capital and paid in surplus, less treasury stock		
16.3 Borrowed funds		
16.4 Net deposits on deposit-type contracts and other insurance liabilities		
16.5 Dividends to stockholders	640,968	672,727
16.6 Other cash provided (applied)	965,172	(986,717
17. Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)		(1,659,444
RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	7,867,521	(9,658,968
19. Cash, cash equivalents and short-term investments:		, , ,
19.1 Beginning of year		43,778,198
19.2 End of year (Line 18 plus Line 19.1)		
Note: Supplemental disclosures of cash flow information for non-cash transactions:	,	,,=•

Note: Supplemental disclosures of cash flow information for non-cash transactions:

20.0001

	1	2	3	4	5	_ 6	7	8	9	10
		Comprehensive				Federal Employees	Title	Title		1
		(Hospital	Medicare	Dental	Vision	Health	XVIII	XIX	Other	Other
	Total	and Medical)	Supplement	Only	Only	Benefits Plans	Medicare	Medicaid	Health	Non-Health
Net premium income	211,916,338	190,275,099					21,641,240			
Change in unearned premium reserves and reserve for rate credit	0									
3. Fee-for-service (net of \$0 medical expenses)	0									XXX
4. Risk revenue	0									XXX
Aggregate write-ins for other health care related revenues	0	0	0		0	0	0	0	0	XXX
Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
7. Total revenues (Lines 1 to 6)	211,916,338	190,275,099	0		0	0	21,641,240	0	0	0
Hospital/medical benefits	154,916,074	125,480,638					29,435,436			XXX
Other professional services	0									XXX
10. Outside referrals	2,092,531	2,092,531								XXX
11. Emergency room and out-of-area	36,895,019	36,513,548					381,471			XXX
12. Prescription drugs	62,031,618	51,972,783					10,058,835			XXX
13. Aggregate write-ins for other hospital and medical	0	0	0 .		0	0	0	0	0	XXX
14. Incentive pool, withhold adjustments and bonus amounts	1,015,051	485,541					529,510			XXX
15. Subtotal (Lines 8 to 14)	256,950,293	216,545,041	0 .		0	0	40,405,252	0	0	XXX
16. Net reinsurance recoveries	78,110,142	56,370,235					21,739,907			XXX
17. Total hospital and medical (Lines 15 minus 16)	178,840,151	160,174,806	0 .		0	0	18,665,345	0	0	XXX
18. Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19. Claims adjustment expenses including \$10,810,486 cost containment expenses	12,046,965	4,683,032					1,870,089		5,493,844	
20. General administrative expenses	23,992,818	17,682,047					2,235,462		4,075,309	
21. Increase in reserves for accident and health contracts	0									XXX
22. Increase in reserve for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23. Total underwriting deductions (Lines 17 to 22)	214,879,934	182,539,885	0		00	0	22,770,896	0	9,569,153	00
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	(2,963,596)	7,735,214	0		00	0	(1,129,656)	0	(9,569,153)	0
			DETAILS OF W	/RITE-INS						
0501	0									XXX
0502.	0									XXX
0503.	0									XXX
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0		0	0	0	0	0	XXX
0599. Total (Lines 0501 through 0503 plus 0598) (Line 5 above)	0	0	0		0	0	0	0	0	XXX
0601	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0602	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698. Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699. Total (Lines 0601 through 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.	0									XXX
1302	0									XXX
1303.	0									XXX
1398. Summary of remaining write-ins for Line 13 from overflow page	0	0	0		0	0	0	0	0	XXX
1399. Total (Lines 1301 through 1303 plus 1398) (Line 13 above)	0	0	0		0	0	0	0	0	XXX

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

	PART I - PREINIUNIS				
		1	2	3	4
					Net Describes
		Direct.	Dainassana	Daireanna	Net Premium
	Literat Desirana	Direct	Reinsurance	Reinsurance	Income
-	Line of Business	Business	Assumed	Ceded	(Cols. 1 + 2 - 3)
1	Comprehensive (hospital and medical).	261,596,847		71,321,748	190,275,099
''	Compression (notice)	201,000,011		1,021,710	100,210,000
2	Medicare Supplement				0
۷.	wedical e Supplement				0
2	Dested only				٥
٥.	Dental only				0
١.	Art.				•
4.	Vision only				0
5.	Federal Employees Health Benefits Plan				0
6.	Title XVIII - Medicare	46,693,462		25,052,222	21,641,240
7.	Title XIX - Medicaid.				0
8.	Other health				0
0.					
q	Health subtotal (Lines 1 through 8)	308 290 308	0	96 373 970	211,916,338
J.	Treath subtotal (Lines + through o).				211,310,000
040	Life				٥
7 10	Life				0
1,,					0
11	Property/casualty				0
12	Totals (Lines 9 to 11)	308,290,308	0	96,373,970	211,916,338

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		FAIN	Z-CLAINS IN	OKKED DUKING	IIIL ILAN					
	1	2 Comprehensive (Hospital	3 Medicare	4 Dental	5 Vision	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9 Other	10 Other
	Total	and Medical)	Supplement	Only	Only	Benefits Plan	Medicare	Medicaid	Health	Non-Health
Payments during the year:										
1.1 Direct	256,632,140	216,535,986					40,096,154			
1.2 Reinsurance assumed	0									
1.3 Reinsurance ceded	81,266,758	59,716,571					21,550,187			
1.4 Net	175,365,382	156,819,415	0	0	0	0 .	18,545,967	0	0	
2. Paid medical incentive pools and bonuses	1,340,046	(490,874)					1,830,920			
3. Claim liability December 31, current year from Part 2A:		, ,								
3.1 Direct	33,126,443	27,622,432					5,504,011			
3.2 Reinsurance assumed	0									
3.3 Reinsurance ceded	7,003,456	4,178,970					2,824,486			
3.4 Net	26,122,987	23,443,462	0	0	0	0	2,679,525	0	0	
Claim reserve December 31, current year from Part 2D:	., ,	2, 2, 2			-		,,			
4.1 Direct	0									
4.2 Reinsurance assumed	0									
4.3 Reinsurance ceded	0									
4.4 Net		0	0	0	0	0	0	0	0	
5. Accrued medical incentive pools and bonuses, current year		2,113,208					1,478,372			
5. Net healthcare receivables (a)	1,509,172	361,324					1,147,848			
7. Amounts recoverable from reinsurers December 31, current year	319,555	319,555					1,147,040			
Claim liability December 31, prior year from Part 2A:										
8.1 Direct	32,314,168	27,737,593					4,576,575			
8.2 Reinsurance assumed		27,737,333					4,570,575			
8.3 Reinsurance ceded	8,748,676	6,113,911					2,634,765			
8.4 Net	23,565,492	21.623.682	0			0	1,941,810	0		
Claim reserve December 31, prior year from Part 2D:	23,303,492	21,023,002	U	0	0	U	1,941,010	U	U	
	0									
9.1 Direct	0									
	0									
9.3 Reinsurance ceded	0		0			0				
			0	0	0	0 .	0	0	0	
Accrued medical incentive pools and bonuses, prior year	3,916,576						2,841,095			
Amounts recoverable from reinsurers December 31, prior year	1,730,951	1,730,951								
2. Incurred benefits:	2== 22= 5:5	040.0=0.==:	_		_		00.0===::	_		
12.1 Direct	255,935,243	216,059,501	0		0	0 .	39,875,742	0]0	
12.2 Reinsurance assumed	0	0	0		0	0 .	0	0]0	
12.3 Reinsurance ceded	78,110,142	56,370,234	0		0	0 .	21,739,908	0	0	
12.4 Net	177,825,101	159,689,267	0		0	0 .	18,135,834	0	0	
Incurred medical incentive pools and bonuses	1,015,050	546,853	0	0	0	0 .	468,197	0	0	

⁽a) Excludes \$......0 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

			17411 271 027411	IO LIADILITI LIVE	OI OOKKELLI IE					
	1	2	3	4	5	6 Federal	7	8	9	10
	Total	Comprehensive (Medical and Hospital)	Medicare Supplement	Dental Only	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
Reported in process of adjustment:										
1.1 Direct	5,468,382	5,045,474					422,908			
1.2 Reinsurance assumed	0									
1.3 Reinsurance ceded	1,377,251	1,126,137					251,114			
1.4 Net	4,091,131	3,919,337	0	0	0	0	171,794	0	0	0
Incurred but unreported:										
2.1 Direct	21,111,038	16,029,935					5,081,103			
2.2 Reinsurance assumed	0									
2.3 Reinsurance ceded	5,626,205	3,052,833					2,573,372			
2.4 Net	15,484,833	12,977,102	0	0	0	0	2,507,731	0	0	0
Amounts withheld from paid claims and capitations:										
3.1 Direct	6,547,023	6,547,023								
3.2 Reinsurance assumed	0									
3.3 Reinsurance ceded										
3.4 Net	6,547,023	6,547,023	0	0	0	0	0	0	0	0
4. Totals:										
4.1 Direct	33,126,443	27,622,432	0	0	0	0	5,504,011	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	7,003,456	4,178,970	0	0	0	0	2,824,486	0	0	0
4.4 Net	26,122,987	23,443,462	0	0	0	0	2,679,525	0	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims F During the		Claim Reserve ar December 31 o		5	6 Estimated Claim
Line of Business	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid December 31 of Prior Year	4 On Claims Incurred During the Year	Claims Incurred in Prior Years (Columns 1 + 3)	Reserve and Claim Liability December 31 of Prior Year
Comprehensive (hospital and medical)	20,598,791	139,416,493	186,164	23,585,682	20,784,955	21,837,347
2. Medicare Supplement					0	
3. Dental only					0	
4. Vision only					0	
Federal Employees Health Benefits Plan					0	
6. Title XVIII - Medicare	1,763,955	20,539,469	17,000	2,334,140	1,780,955	1,728,144
7. Title XIX - Medicaid					0	
8. Other health					0	
9. Health subtotal (Lines 1 to 8)	22,362,746	159,955,962	203,164	25,919,822	22,565,910	23,565,491
10. Healthcare receivables (a)		7,051,102			0	
11. Other non-health					0	
12. Medical incentive pools and bonus amounts	2,765,557	(1,425,511)	705,796	2,885,784	3,471,353	3,916,577
13. Totals (Lines 9 - 10 + 11 + 12)	25,128,303	151,479,349	908,960	28,805,606	26,037,263	27,482,068

⁽a) Excludes \$......0 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED CLAIMS

(000 Omitted)

SECTION A - PAID HEALTH CLAIMS - GRAND TOTAL

			Cumulative Net Amounts Paid										
Year in Which Losses	1	2	3	4	5								
Were Incurred	2015	2016	2017	2018	2019								
1. Prior	15,623	15,596	15,596	15,596	15,596								
2. 2015	133,661	153,921	154,052	154,052	154,052								
3. 2016	XXX	152,781	175,707	173,246	170,997								
4. 2017	XXX	XXX	161,916	174,476	174,564								
5. 2018	XXX	XXX	XXX	176,948	199,223								
6. 2019	XXX	XXX	XXX	XXX	159,955								

SECTION B - INCURRED HEALTH CLAIMS - GRAND TOTAL

		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year								
_	Year in Which Losses	1	2	3	4	5				
N	Were Incurred	2015	2016	2017	2018	2019				
	1. Prior	149,323	3148,775	148,775	148,775	148,775				
ĭ	2. 2015	154,563	3153,765	154,052	154,052	154,052				
Ī	3. 2016	XXX		173,869	173,246	170,997				
	4. 2017	XXX	xxx	175,446	174,491	174,564				
	5. 2018	XXX	XXX	XXX	200,425	199,426				
	6. 2019	XXX	XXX	XXX	XXX	185,876				

SECTION C - INCURRED YEAR HEALTH CLAIM AND CLAIM ADJUSTMENT EXPENSE RATIO - GRAND TOTAL

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in Which					Adjustment			Unpaid Claim	Claims Adjustment	
Premiums were Earned and	Premiums	Claim	Claim Adjustment	Percent	Expense Payments	Percent	Claims	Adjustment	Expense Incurred	Percent
Claims were Incurred	Earned	Payments	Expense Payments	(Col. 3/2)	(Col. 2 + 3)	(Col. 5/1)	Unpaid	Expense	(Col. 5 + 7 + 8)	(Col. 9/1)
1. 2015	177,319	154,052	4,943	3.2	158,995	89.7			158,995	89.7
2. 2016	191,141	170,997	7,985	4.7	178,982	93.6			178,982	93.6
3. 2017	206,662	174,564	7,502	4.3	182,066	88.1			182,066	88.1
4. 2018	226,791	199,223	6,248	3.1	205,471	90.6	909	13	206,393	91.0
5. 2019	211,916	159,955	6,553	4.1	166,508	78.6	28,806	400	195,714	92.4

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED CLAIMS

(\$000 Omitted)

SECTION A - PAID HEALTH CLAIMS - HOSPITAL AND MEDICAL

	Cumulative Net Amounts Paid							
Year in Which Losses	1	2	3	4	5			
Were Incurred	2015	2016	2017	2018	2019			
1. Prior	148,781	148,775	148,775	148,775	148,775			
2. 2015	133,483	153,921	154,052	154,052	154,052			
3. 2016	XXX	151,307	170,971	170,997	170,997			
4. 2017	XXX	XXX	146,792	166,261	166,349			
5. 2018	XXX	XXX	XXX	164,520	185,031			
6. 2019	XXX	XXX	XXX	XXX	139,416			

SECTION B - INCURRED HEALTH CLAIMS - HOSPITAL AND MEDICAL

Ī		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year								
_	Year in Which Losses	1	2	3	4	5				
N	Were Incurred	2015	2016	2017	2018	2019				
Ξ	1. Prior	149,323	148,775	148,775	148,775	148,775				
₹	2. 2015	154,563	153,765	154,052	154,052	154,052				
	3. 2016	XXX	167,513	171,642	170,997	170,997				
	4. 2017	XXX	XXX	166,620	166,244	166,349				
	5. 2018	XXX	XXX	XXX	186,279	185,227				
	6. 2019	XXX	XXX	XXX	XXX	163,002				

SECTION C - INCURRED YEAR HEALTH CLAIM AND CLAIM ADJUSTMENT EXPENSE RATIO - HOSPITAL AND MEDICAL

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in Which					Adjustment			Unpaid Claim	Claims Adjustment	
Premiums were Earned and	Premiums	Claim	Claim Adjustment	Percent	Expense Payments	Percent	Claims	Adjustment	Expense Incurred	Percent
Claims were Incurred	Earned	Payments	Expense Payments	(Col. 3/2)	(Col. 2 + 3)	(Col. 5/1)	Unpaid	Expenses	(Col. 5 + 7 + 8)	(Col. 9/1)
1. 2015	177,319	154,052	4,943	3.2	158,995	89.7			158,995	89.7
2. 2016	185,994	170,997	7,719	4.5	178,716	96.1			178,716	96.1
3. 2017	194,468	166,349	6,326	3.8	172,675	88.8			172,675	88.8
4. 2018	207.548	185,031	4.623	2.5	189,654	91.4	186	2	189,842	91.5
5. 2019	190,275	<i>'</i>	4,683	3.4	144,099	75.7	25,700	352	170,151	89.4

Underwriting and Investment Ex. - Pt. 2C - Development of Paid Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development of Incurred Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development Ratio Incurred Year Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development of Paid Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development of Incurred Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development Ratio Incurred Year Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development of Paid Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development of Incurred Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development Ratio Incurred Year Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development of Paid Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development of Incurred Health Claims NONE

Underwriting and Investment Ex. - Pt. 2C - Development Ratio Incurred Year Health Claims NONE

12.MS, 12.DO, 12.VO, 12.FE

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED CLAIMS

(\$000 Omitted)

SECTION A - PAID HEALTH CLAIMS - TITLE XVIII - MEDICARE

	Cumulative Net Amounts Paid								
Year in Which Losses	1	2	3	4	5				
Were Incurred	2015	2016	2017	2018	2019				
1. Prior									
2. 2015									
3. 2016	XXX	1,474	2,220	2,249					
4. 2017	XXX	XXX	7,394	8,215	8,215				
5. 2018	XXX	XXX	XXX	12,428	14,192				
6. 2019	XXX	XXX	XXX	XXX	20,539				

SECTION B - INCURRED HEALTH CLAIMS - TITLE XVIII - MEDICARE

		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year								
_	Year in Which Losses	1	2	3	4	5				
N	Were Incurred	2015	2016	2017	2018	2019				
1	l. Prior									
2	2. 2015									
] 3	3. 2016	XXX	1,945	2,227	2,249					
4	l. 2017	XXX	XXX	8,826	8,247	8,215				
5	5. 2018	XXX	XXX	XXX	14,146	14,199				
6	5. 2019	XXX	XXX	XXX	XXX	22,874				

SECTION C - INCURRED YEAR HEALTH CLAIM AND CLAIM ADJUSTMENT EXPENSE RATIO - TITLE XVIII - MEDICARE

	1	2	3	4	5	6	7	8	9	10
					Claim and Claim				Total Claims and	
Years in Which					Adjustment			Unpaid Claim	Claims Adjustment	
Premiums were Earned and	Premiums	Claim	Claim Adjustment	Percent	Expense Payments	Percent	Claims	Adjustment	Expense Incurred	Percent
Claims were Incurred	Earned	Payments	Expense Payments	(Col. 3/2)	(Col. 2 + 3)	(Col. 5/1)	Unpaid	Expenses	(Col. 5 + 7 + 8)	(Col. 9/1)
1. 2015		0		0.0	0	0.0			0	0.0
2. 2016	5.147	0	266	0.0	266	5.2			266	5.2
3. 2017	12,194	8,215	1.176	14.3	9.391	77.0			9.391	77.0
4. 2018	19.243	14.192	1.625	11.5	15.817	82.2	723	11	16,551	86.0
5. 2019	21,641	20,539	1,870	9.1	22,409			48	25,563	118.1

Underwriting and Investment Ex.	- Pt. 2C - Development of Paid Health Claims NONE
Underwriting and Investment Ex Pt.	2C - Development of Incurred Health Claims NONE
Underwriting and Investment Ex Pt. 2C	- Development Ratio Incurred Year Health Claims NONE
Underwriting and Investment Ex.	- Pt. 2C - Development of Paid Health Claims NONE
Underwriting and Investment Ex Pt.	2C - Development of Incurred Health Claims NONE
Underwriting and Investment Ex Pt. 2C	- Development Ratio Incurred Year Health Claims NONE

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1 Total	2 Comprehensive (Hospital and Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other
Unearned premium reserves	0								
Additional policy reserves (a)	0								
Reserve for future contingent benefits	0								
Reserve for rate credits or experience rating refunds (including \$0 for investment income)	135,394	135,394							
Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	0
6. Totals (gross)	135,394	135,394	0	0	0	0	0	0	0
7. Reinsurance ceded	0								
8. Totals (net) (Page 3, Line 4)	135,394	135,394	0	0	0	0	0	0	0
9. Present value of amounts not yet due on claims	0								
10. Reserve for future contingent benefits	0								
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0 .	0	0	0
12. Totals (gross)	0	0	0	0	0	0	0	0	0
43. Reinsurance ceded	0								
14. Totals (net) (Page 3, Line 7)	0	0	0	0	0	0	0	0	0
			DETAILS OF	WRITE-INS					
0501	0								
0502	0								
0503	0								
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0
0599. Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0
1101	0								
1102	0								
1103	0								
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)		0	0	0	0	0	0	0	0

⁽a) Includes \$.....0 premium deficiency reserve.

Statement as of December 31, 2019 of the **HMO Partners, Inc UNDERWRITING AND INVESTMENT EXHIBIT**

PART 3 - ANALYSIS OF EXPENSES

	PART 3 - ANALYSIS OF EXPENSES Claim Adjustment Expenses			3	4	5
		1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$0 for occupancy of own building)	25,536	82,166	679,439		787,141
2.	Salaries, wages and other benefits	12,569,513	2,628,455	35,465,409		50,663,377
3.	Commissions (less \$0 ceded plus \$0 assumed)			5,391,613		5,391,613
4.	Legal fees and expenses	1,522		186,758		188,280
5.	Certifications and accreditation fees	3,433				3,433
6.	Auditing, actuarial and other consulting services	457,433		2,201,701		2,659,134
7.	Traveling expenses	147,391	7,793	446,776		601,960
8.	Marketing and advertising	(4,289)	394	595,237		591,342
9.	Postage, express and telephone	105,648	666,356	1,007,973		1,779,977
10.	Printing and office supplies	103,580	20,952	576,025		700,557
11.	Occupancy, depreciation and amortization	165,681	37,986	392,212		595,879
12.	Equipment	47,474	6,291	328,333		382,098
13.	Cost or depreciation of EDP equipment and software	1,193,399	447,842	8,530,412		10,171,653
14.	Outsourced services including EDP, claims, and other services	4,896,667	(188,362)	4,429,711	146,945	9,284,961
15.	Boards, bureaus and association fees	51,172	1,105	665,401		717,678
16.	Insurance, except on real estate	195,552	11,782	276,744		484,078
17.	Collection and bank service charges			114,006		114,006
18.	Group service and administration fees	1,919,301	203,528	217,119		2,339,948
19.	Reimbursements by uninsured plans	(2,461,984)	(456,155)	(18,026,518)		(20,944,657)
20.	Reimbursements from fiscal intermediaries		272,948			272,948
21.	Real estate expenses	125,807	33,262	512,010		671,079
22.	Real estate taxes	14,686	3,584	44,195		62,465
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes		21,229	46,539		67,771
	23.2 State premium taxes			1,291,768		1,291,768
	23.3 Regulatory authority licenses and fees	4,139		134,029		138,168
	23.4 Payroll taxes	670,332	143,267	1,657,865		2,471,464
	23.5 Other (excluding federal income and real estate taxes)	4,757	1,926	55,219		61,902
24.	Investment expenses not included elsewhere					0
25.	Aggregate write-ins for expenses	(9,426,265)	(2,709,872)	(23,227,159)	0	(35,363,296)
26.	Total expenses incurred (Lines 1 to 25)	10,810,488	1,236,477	23,992,817	146,945	(a)36,186,727
27.	Less expenses unpaid December 31, current year		412,902	3,578,013		3,990,916
28.	Add expenses unpaid December 31, prior year			3,313,477		3,785,205
29.	Amounts receivable relating to uninsured plans, prior year					6,593
30.	Amounts receivable relating to uninsured plans, current year					0
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)					35,974,423
		AILS OF WRITE-INS	<u>'</u>			
2501.	Administrative Service Agreement			2,925,606		2,925,606
	Unpaid Claims Processing					(58,826)
	Ceded Administrative Expense					
	Summary of remaining write-ins for Line 25 from overflow page					
1			(2,709,872)			

⁽a) Includes management fees of \$.......0 to affiliates and \$......0 to non-affiliates.

Statement as of December 31, 2019 of the **HMO Partners, Inc EXHIBIT OF NET INVESTMENT INCOME**

	2,411211 01 1121 1111 2011112111		·· -		
			1 Collected During Year		2 Earned During Year
1.	U.S. government bonds.	(a)			462,906
1.1	Bonds exempt from U.S. tax	, ,			
1.2	Other bonds (unaffiliated).		1.121.149		1.145.016
1.3	Bonds of affiliates.	, ,			
2.1	Preferred stocks (unaffiliated)	(-)			
2.11	Preferred stocks of affiliates	٠,			
2.2	Common stocks (unaffiliated)	٠,	220.117		220,831
2.21	Common stocks of affiliates				
3.	Mortgage loans	(c)			
4.	Real estate	(d)			
5.	Contract loans				
6.	Cash, cash equivalents and short-term investments	(e)	114,337		560,657
7.	Derivative instruments	(f)			
8.	Other invested assets		199,000		199,000
9.	Aggregate write-ins for investment income		0		0
10.	Total gross investment income		2,119,649		2,588,410
11.	Investment expenses			(g)	146,945
12.	Investment taxes, licenses and fees, excluding federal income taxes			(g)	
13.	Interest expense			(h)	
14.	Depreciation on real estate and other invested assets			(i)	0
15.	Aggregate write-ins for deductions from investment income				0
16.	Total deductions (Lines 11 through 15)				146,945
17.	Net investment income (Line 10 minus Line 16)				2,441,466
	DETAILS OF WRITE-INS				
0901.					
0902.					
0903.					
	Summary of remaining write-ins for Line 9 from overflow page		0		0
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9 above)		0		0
1501.					
1502.					
1503.					
1598.	Summary of remaining write-ins for Line 15 from overflow page				0
1599.	Totals (Lines 1501 through 1503 plus 1598) (Line 15 above)				0
(a)	Includes \$76,736 accrual of discount less \$203,005 amortization of premium and less \$68,996 paid for accru	ed interest	on purchases.		
(b)	Includes \$0 accrual of discount less \$0 amortization of premium and less \$0 paid for accrued divide	nds on pur	chases.		
(c)	Includes \$0 accrual of discount less \$0 amortization of premium and less \$0 paid for accrued interesting the second of the s	st on purch	ases.		
(d)	Includes \$0 for company's occupancy of its own buildings; and excludes \$0 interest on encumbrances.				
(e)	Includes \$0 accrual of discount less \$0 amortization of premium and less \$0 paid for accrued interesting the second of the	st on purch	ases.		
(f)	Includes \$0 accrual of discount less \$0 amortization of premium.				
(g)	Includes \$0 investment expenses and \$0 investment taxes, licenses and fees, excluding federal income tax	axes, attribu	utable to segregated and S	Separate	e Accounts.
(h)	Includes \$0 interest on surplus notes and \$0 interest on capital notes.				
(i)	Includes \$0 depreciation on real estate and \$0 depreciation on other invested assets.				
	•				

EXHIBIT OF CAPITAL GAINS (LOSSES)

		1	2	3	4	5
		Realized	_		·	Change in
		Gain (Loss)	Other	Total Realized	Change in	Unrealized
		on Sales	Realized	Capital Gain (Loss)	Unrealized	Foreign Exchange
		or Maturity	Adjustments	(Columns 1 + 2)	Capital Gain (Loss)	Capital Gain (Loss)
1.	U.S. government bonds	(1,400)		(1,400)		
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	10,855		10,855		
1.3	Bonds of affiliates			0		
2.1	Preferred stocks (unaffiliated)			0		
2.11	Preferred stocks of affiliates			0		
2.2	Common stocks (unaffiliated)	(62,605)		(62,605)	680,300	
2.21	Common stocks of affiliates			0		
3.	Mortgage loans			0		
4.	Real estate			0		
5.	Contract loans			0		
6.	Cash, cash equivalents and short-term investments	402		402		
7.	Derivative instruments			0		
8.	Other invested assets	(50,582)		(50,582)	1,815,933	
9.	Aggregate write-ins for capital gains (losses)	0	0	0	67,261	0
10.	Total capital gains (losses)	(103,331)	0	(103,331)	2,563,494	0
		DETAILS (F WRITE-INS			
0004	000				07.004	

	DETAILS OF WINTE-INS										
0901.	SSP			0	67,261						
0902.				0							
0903.				0							
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0					
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9 above)	0	0	0	67,261	0					

Statement as of December 31, 2019 of the HMO Partners, Inc EXHIBIT OF NONADMITTED ASSETS

		1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)			0
2.	Stocks (Schedule D):			
	2.1 Preferred stocks			0
	2.2 Common stocks			0
3.	Mortgage loans on real estate (Schedule B):			
	3.1 First liens			0
	3.2 Other than first liens			0
4.	Real estate (Schedule A):			
	4.1 Properties occupied by the company			0
	4.2 Properties held for the production of income			0
	4.3 Properties held for sale			0
5.	Cash (Schedule E-Part 1), cash equivalents (Schedule E-Part 2) and short-term investments (Schedule DA)			0
6.	Contract loans			0
7.	Derivatives (Schedule DB)			0
8.	Other invested assets (Schedule BA)			0
9.	Receivables for securities			0
10.	Securities lending reinvested collateral assets (Schedule DL)			0
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection			0
	15.2 Deferred premiums, agents' balances and installments booked but			
	deferred and not yet due			0
	15.3 Accrued retrospective premiums and contracts subject to redetermination	68,174	12,460	(55,715
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			0
	16.2 Funds held by or deposited with reinsured companies			0
	16.3 Other amounts receivable under reinsurance contracts			
17.	Amounts receivable relating to uninsured plans		376	376
18.1	Current federal and foreign income tax recoverable and interest thereon			0
18.2	Net deferred tax asset		•	,
19.	Guaranty funds receivable or on deposit			0
20.	Electronic data processing equipment and software			0
21.	Furniture and equipment, including health care delivery assets			0
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0
23.	Receivables from parent, subsidiaries and affiliates			
24.	Health care and other amounts receivable	1,912,480	958,945	(953,534
25.	Aggregate write-ins for other-than-invested assets	700,000	700,000	0
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected			
	Cell Accounts (Lines 12 through 25)			
	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28.	TOTALS (Lines 26 and 27)	2,680,654	1,795,569	(885,085
	DETAILS OF W	RITE-INS		
1101				0
1102				0
	Summary of remaining write-ins for Line 11 from overflow page			
1199	Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)	0	0	0
2501	Other Assets	700,000	700,000	0
2502				0
2503				0
2598	Summary of remaining write-ins for Line 25 from overflow page	0	0	0
2500	Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	700.000	700.000	0

Statement as of December 31, 2019 of the HMO Partners, Inc EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

	Total Members at End of						
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months	
Health maintenance organizations		7,908	7,746	7,682	7,623	93,1	
Provider service organizations							
Preferred provider organizations							
4. Point of service.		56,299	54,119	53,014	51,009	649.98	
5. Indemnity only			,	,	,	,	
Aggregate write-ins for other lines of business.		0	0	0	0		
7. Total		64,207	61,865	60,696	58,632	743,10	
	DETAI	LS OF WRITE-INS	· ,	·		·	
601							
602							
603							
0698. Summary of remaining write-ins for Line 6 from overflow page		U .		0	0		

NOTES TO FINANCIAL STATEMENTS

Note 1 - Summary of Significant Accounting Policies and Going Concern

Accounting Practices

The financial statements of the company are presented on the basis of accounting practices prescribed or permitted by the Arkansas Insurance Department.

The Arkansas Insurance Department recognizes only statutory accounting practices prescribed or permitted by the state of Arkansas for determining and reporting the financial condition and results of operations of an insurance company, for determining its solvency under the Arkansas Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures manual, version effective January 1, 2001, (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the state of Arkansas.

	SSAP#	F/S Page	F/S Line #	2019	2018
NET INCOME				•	
(1) Company state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ (897,500)	\$ 6,409,699
(2) State Prescribed Practices that are an increase/(decrease) from NAIC SAP					
				\$	\$
(3) State Permitted Practices that are an increase/(decrease) from NAIC SAP					
				\$	\$
(4) NAIC SAP (1 – 2 – 3 = 4)	XXX	XXX	XXX	\$ (897,500)	\$ 6,409,699
SURPLUS					
(5) Company state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 68,543,030	\$ 68,141,934
(6) State Prescribed Practices that are an increase/(decrease) from NAIC SAP					
				\$	\$
(7) State Permitted Practices that are an increase/(decrease) from NAIC SAP					
				\$	\$
(8) NAIC SAP (5 – 6 – 7 = 8)	XXX	XXX	XXX	\$ 68,543,030	\$ 68,141,934

B. Use of Estimates in the Preparation of the Financial Statement

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

Accounting Policy C.

Health premiums are earned ratably over the terms of the related insurance and reinsurance contracts or polices. Expenses incurred in connection with acquiring new insurance business are charged to operations as incurred.

In addition, the company uses the following accounting policies:

(1) Basis for Short-Term Investments

Short-term investments are stated at amortized cost.

(2) Basis for Bonds and Amortization Schedule

Bonds not backed by other loans are stated at amortized cost using the interest method.

(3) Basis for Common Stocks

Common Stock is stated at market except that investments in stocks of uncombined subsidiaries and affiliates in which the Company has an interest of 20% or more are carried on the equity basis.

(4) Basis for Preferred Stocks

The Company does not have preferred stock.

(5) Basis for Mortgage Loans

The Company does not have Mortgage Loans.

(6) Basis for Loan-Backed Securities and Adjustment Methodology

Loan-backed securities are stated at either amortized cost or the lower of amortized cost or fair value. The prospective adjustment method is used to value all securities.

NOTES TO FINANCIAL STATEMENTS

(7) Accounting Policies for Investments in Subsidiaries, Controlled and Affiliated Entities

The Company does not have any investments in subsidiaries.

(8) Accounting Policies for Investments in Joint Ventures, Partnerships and Limited Liability Entities

The Company does not have any investments in subsidiaries.

(9) Accounting Policies for Derivatives

The Company does not have any derivatives.

(10) Anticipated Investment Income Used in Premium Deficiency Calculation

The Company does not anticipate investment income as a factor in the premium deficiency calculation.

(11) Management's Policies and Methodologies for Estimating Liabilities for Losses and Loss/Claim Adjustment Expenses

When setting reserves, the Company employs the 5 methods that are described below. Based on the estimates of these methods and also retrospective considerations, the company sets a best estimate and then an explicit margin is added to ensure that the estimate is sufficient. The average of the methods, as well as the spread of the estimates, is also considered when setting the respective liabilities. Aggregate liabilities are tested against other aggregate estimation methods to check for reasonableness, and any additional margin or adjustments are made.

- Aggregate Method: 12 months of paid claims are subtracted from 12 months of estimated incurred claims to get the liability estimate.
- b. 3 Month Average Method: For the base liability estimate, the average liability of the third, fourth, and fifth month prior to the current month is used. Adjustments are made for trend, membership change, and backlog to determine the current month's estimate of liability.
- Previous Year's IBNR Method: This method is similar to the Three Month Average Method, except that the actual reserve from one year ago is used as the base estimate of liability. This is projected forward using adjustments for trend, membership change, and backlog.
- d. CY Lag Method: This method calculates completion factors by incurral year. Completion factors used for the current year are based on the previous year's experience. Completion factors for the most recent 3 years are set manually.
- 12 Month CF Method: This method is identical to the CY Lag Method, except that historical completion factors are based on 12 months of rolling data.
- (12) Changes in the Capitalization Policy and Predefined Thresholds from Prior Period

The Company has not modified its capitalization policy from the prior period.

(13) Method Used to Estimate Pharmaceutical Rebate Receivables

Pharmacy rebate receivable estimates are based upon the prior quarter's invoiced amounts.

D. Going Concern

> For the period ending December 31, 2019 management has evaluated the Company's ability to continue as a going concern. Management has concluded that there is not substantial doubt that the Company can continue as a going concern, therefore, there are no policies in place to alleviate such situations.

Note 2 – Accounting Changes and Correction of Errors

The Company prepares its statutory financial statements in conformity with accounting practices prescribed or permitted by the State of Arkansas. Effective January 1, 2001, the State of Arkansas adopted that insurance companies domiciled in the State of Arkansas prepare their statutory basis financial statements in accordance with the NAIC Accounting Practices and Procedures manual Version effective January 1, 2001 subject to any deviations prescribed or permitted by the State of Arkansas insurance commissioner.

Accounting changes adopted to conform to the provisions of the NAIC Accounting Practices and Procedures manual - Version effective January 1, 2001 are reported as changes in accounting principles. The cumulative effect of changes in accounting principles is reported as an adjustment to unassigned funds (surplus) in the period of the change in accounting principle.

There were no accounting changes or correction of errors from the prior period.

Note 3 - Business Combinations and Goodwill

A. Statutory Purchase Method

N/A

В.	Stat	utory Merger
	N/A	A
C.	Ass	umption Reinsurance
	N/2	A
D.	Imp	airment Loss
	N/A	A
Note 4 -	- Disco	ontinued Operations
A.	Disc	continued Operation Disposed of or Classified as Held for Sale
	N/A	·
B.	Cha	nge in Plan of Sale of Discontinued Operation
	N/A	A
C.	Natı	ure of any Significant Continuing Involvement with Discontinued Operations After Disposal
	N/A	Λ
D.	Equ	ity Interest Retained in the Discontinued Operation After Disposal
	N/A	A
Note 5 -	- Inves	tments
A.		tgage Loans, including Mezzanine Real Estate Loans
	N/A	\mathbf{A}
В.	Deb	t Restructuring
	Th	e Company has no debt restructuring at this time.
C.	Rev	erse Mortgages
	The	e Company has no reverse mortgages at this time.
D.	Loa	n-Backed Securities
	(1)	Description of Sources Used to Determine Prepayment Assumptions
		For fixed-rate agency mortgage-backed securities, Clearwater Analytics calculates prepayment speeds utilizing Mortgage Industry Advisory Corporation (MIAC) Mortgage Industry Medians (MIMs). MIMs are derived from a semi-monthly dealer-consensus survey of long-term prepayment projections. For other mortgage-backed, loan-backed, and structured securities, Clearwater utilizes prepayment assumptions from Moody's Analytics. Moody's applies a flat economic credit model and utilizes a vector of multiple monthly speeds as opposed to a single speed for more robust projections. In instances where Moody's projections are not available, Clearwater uses data from Reuters, which utilizes the median prepayment speed from contributors' models.
	(2)	Other-Than-Temporary Impairments
		N/A
	(3)	Recognized OTTI Securities
		N/A
	(4)	All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized in earnings as a realized loss (including securities with a recognized other-than-temporary impairment for non-interest related declines when a non-recognized

interest related impairment remains):

Г	a.	The aggregate amount of unrealized losses:	1. Less than 12 Months	\$ 4,719
			2. 12 Months or Longer	\$
	b.	The aggregate related fair value of securities with unrealized losses:	1. Less than 12 Months	\$ 504,686
			2. 12 Months or Longer	\$

(5) Information Investor Considered in Reaching Conclusion that Impairments are Not Other-Than-Temporary

N/A

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

The Company has no repurchase agreements and/or security lending transactions at this time.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing Repurchase Transaction – Cash Taker – Overview of Secured Borrowing Transactions

The Company has no Repurchase Agreements Transactions Accounted for as Secured Borrowing.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing Repurchase Transactions – Cash Provider – Overview of Secured Borrowing Transactions

The Company has no Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

H. Repurchase Agreements Transactions Accounted for as a Sale Repurchase Transaction – Cash Taker – Overview of Sale Transactions

The Company has no Repurchase Agreements Transactions Accounted for as a Sale.

 Reverse Repurchase Agreements Transactions Accounted for as a Sale Repurchase Transaction – Cash Provider – Overview of Sale Transactions

The Company has no Working Capital Finance Investments at this time.

J. Real Estate

The Company has no investments in real estate at this time.

K. Low-Income Housing Tax Credits (LIHTC)

The Company has no investments in low-income housing tax credits.

L. Restricted Assets

The Company has no restricted assets at this time.

M. Working Capital Finance Investments

The Company has no Working Capital Finance Investments at this time.

N. Offsetting and Netting of Assets and Liabilities

The Company does not offset or net Assets and Liabilities.

O. 5GI Securities

The Company does not hold 5* Securities at this time.

P. Short Sales

Not Applicable

Q. Prepayment Penalty and Acceleration Fees

The Company does not have any prepayment penalty or acceleration fees.

(1)	Number of CUSIPs	
(2)	Aggregate Amount of Investment Income	\$

Investments in Joint Ventures, Partnerships and Limited Liability Companies that Exceed 10% of Ownership A.

The Company has no investments in Joint Ventures, Partnerships, or Limited Liability Companies that exceed 10% of its admitted assets.

Investments in Impaired Joint Ventures, Partnerships and Limited Liability Companies

res, Partnerships, and Limited

		ompany did not recognize any impairment write down for its investments in Joint Ventur ty Companies during the statement period.
Note 7	– Investme	nt Income
A.	The bas	es, by category of investment income, for excluding (nonadmitting) any investment income due and accrued:
	N/A	
В.		I amount excluded:
	N/A	
Note 8	– Derivativ	e Instruments
This	company	does not have Derivative Instruments.
A.	Derivativ	ves Under SSAP No. 86 – Derivatives
	(1)	Market Risk, Credit Risk and Cash Requirements
		None
	(2)	Objectives for Derivative Use
	(2)	None Accounting Deligion for Decorption and Massurement
	(3)	Accounting Policies for Recognition and Measurement
		None
	(4)	Identification of Whether Derivative Contracts with Financing Premiums
		None
	(5)	Net Gain or Loss Recognized
		None
	(6)	Net Gain or Loss Recognized from Derivatives that no Longer Qualify for Hedge Accounting
		N
	(7)	None Derivatives Accounted for as Cash Flow Hedges
	(1)	(a)
		None
		(b)
		None

Total Premium Costs for Contracts

(8)

None

Derivatives under SSAP No. 108 – Derivatives Hedging Variable Annuity Guarantees

None

Note 9 - Income Taxes

Deferred Tax Assets/(Liabilities)

1. Components of Net Deferred Tax Asset/(Liability)

. Components of Net Deferred Tax Asset/(Liability)										
			2019			2018			Change	
		1	2	3	4	5	6	7	8	9
				(Col 1+2)			(Col 4+5)	(Col 1-4)	(Col 2-5)	(Col 7+8)
		Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
a.	Gross deferred tax									
	assets	\$ 2,266,869	\$	\$ 2,266,869	\$ 1,410,793	\$	\$ 1,410,793	\$ 856,076	\$	\$ 856,076
b.	Statutory valuation									
	allowance									
	adjustment									
C.	Adjusted gross									
	deferred tax assets									
	(1a-1b)	\$ 2,266,869	\$	\$ 2,266,869	\$ 1,410,793	\$	\$ 1,410,793	\$ 856,076	\$	\$ 856,076
d.	Deferred tax assets									
	nonadmitted				123,789		123,789	(123,789)		(123,789)
e.	Subtotal net									
	admitted deferred									
	tax asset (1c-1d)	\$ 2,266,869	\$	\$ 2,266,869	\$ 1,287,004	\$	\$ 1,287,004	\$ 979,865	\$	\$ 979,865
f.	Deferred tax									
	liabilities	1,414	1,017,887	1,019,301	1,264	405,238	406,502	150	612,649	612,799
g.	Net admitted									
	deferred tax									
	assets/(net deferred									
	tax liability) (1e-1f)	\$ 2,265,455	\$ (1,017,887)	\$ 1,247,568	\$ 1,285,740	\$ (405,238)	\$ 880,502	\$ 979,715	\$ (612,649)	\$ 367,066

2. Admission Calculation Components SSAP No. 101

			2019		2018					
		1	2	3 (Col 1+2)	4	5	6 (Col 4+5)	7 (Col 1-4)	8 (Col 2-5)	9 (Col 7+8)
		Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
 Federal income taxes paid in pr years recoveral through loss carrybacks 	ior	5 1,148,855	\$	\$ 1,148,855	\$ 880,502	\$ 880,502	\$ 1,761,004	\$ 268,353	\$ (880,502)	\$ (612,149)
b. Adjusted gross deferred tax as expected to be realized (exclude	sets	279,300		279,300				279,300		279,300
				2	26.5					

		2019			2018			Change	
	1	2	3	4	5	6	7	8	9
			(Col 1+2)			(Col 4+5)	(Col 1-4)	(Col 2-5)	(Col 7+8)
	Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
the amount of									
deferred tax assets									
from 2(a) above)									
after application of the threshold									
limitation. (The									
lesser of 2(b)1 and									
2(b)2 below)									
Adjusted gross									
deferred tax									
assets									
expected to be									
realized									
following the									
balance sheet	0=0.000						0=0.000		0=0.000
date	279,300		279,300				279,300		279,300
Adjusted gross deferred tax									
assets allowed									
per limitation									
threshold									
c. Adjusted gross									
deferred tax assets									
(excluding the									
amount of deferred									
tax assets from 2(a)									
and 2(b) above)									
offset by gross deferred tax									
liabilities	838,713		838,713	406,502	406,502	813,004	432,211	(406,502)	25,709
d. Deferred tax assets	030,113		030,713	400,302	400,302	013,004	452,211	(400,302)	25,109
admitted as the									
result of application									
of SSAP 101.									
Total									
(2(a)+2(b)+2(c))	\$ 2,266,868	\$	\$ 2,266,868	\$ 1,287,004	\$ 1,287,004	\$ 2,574,008	\$ 979,864	\$ (1,287,004)	\$ (307,140)

3. Other Admissibility Criteria

		2019	2018
a.	Ratio percentage used to determine recovery period and threshold limitation amount	827.7%	792.0%
b.	Amount of adjusted capital and surplus used to determine recovery period and threshold		
	limitation in 2(b)2 above	\$ 61,636,371	\$ 65,208,490

4. Impact of Tax Planning Strategies

(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.

		2019		2018	}	Change		
		1	2	3	4	5	6	
						(Col. 1-3)	(Col. 2-4)	
		Ordinary	Capital	Ordinary	Capital	Ordinary	Capital	
1.	Adjusted gross DTAs amount from Note 9A1(c)	\$ 2,266,869	\$	\$ 1,410,793	\$	\$ 856,076	\$	
2.	Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	%						
3.	Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)	\$ 2,266,869	\$	\$ 1,287,004	\$	\$ 979,865	\$	
4	Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning							
	strategies	%	%	%	%	%	%	

(b) Does the company's tax planning strategies include the use of reinsurance? $\underline{\text{NO}}$

B. Deferred Tax Liabilities Not Recognized

1. The types of temporary differences for which a DTL has not been recognized and the types of events that would cause those temporary differences to become taxable are:

N/A

 $2. \hspace{0.5cm} \hbox{The cumulative amount of each type of temporary difference is:} \\$

N/A

The amount of the unrecognized DTL for temporary differences related to investments in foreign subsidiaries and foreign corporate joint ventures that are essentially permanent in duration, if determination of that liability is practicable, or a statement that determination is not practicable are:

4. The amount of the DTL for temporary differences other than those in item (3) above that is not recognized is:

N/A

Current and Deferred Income Taxes C.

Current Income Tax

Current income rax			
	1	2	3
			(Col 1-2)
	2019	2018	Change
a. Federal	\$ 546,203	\$ 1,135,730	\$ (589,527)
b. Foreign	\$	\$	\$
c. Subtotal	\$ 546,203	\$ 1,135,730	\$ (589,527)
d. Federal income tax on net capital gains	\$ 21,699	\$ 1,575,955	\$ (1,554,256)
e. Utilization of capital loss carry-forwards	\$	\$	\$
f. Other	\$ (34,617)	\$ (28)	\$ (34,589)
g. Federal and Foreign income taxes incurred	\$ 533,285	\$ 2,711,657	\$ (2,178,372)

2.

Deferred Tax Assets			
	1	2	3
			(Col 1-2)
	2019	2018	Change
a. Ordinary:			
Discounting of unpaid losses	\$ 136,459	\$ 153,026	\$ (16,567)
Unearned premium reserve	131,666	144,565	(12,899)
Policyholder reserves			
4. Investments			
Deferred acquisition costs			
Policyholder dividends accrual			
7. Fixed assets			
Compensation and benefits accrual	739,953	702,711	37,242
9. Pension accrual			
10. Receivables - nonadmitted	648,634	351,074	297,560
11. Net operating loss carry-forward			
12. Tax credit carry-forward			
13. Other (items <=5% and >5% of total ordinary tax assets)	610,157	59,417	550,740
Other (items listed individually >5% of total ordinary tax assets)			
99. Subtotal	\$ 2,266,869	\$ 1,410,793	\$ 856,076
b. Statutory valuation allowance adjustment			
c. Nonadmitted		123,789	(123,789)
d. Admitted ordinary deferred tax assets (2a99-2b-2c)	\$ 2,266,869	\$ 1,287,004	\$ 979,865
e. Capital:			•
1. Investments	\$	\$	\$
Net capital loss carry-forward			
3. Real estate			
4. Other (items <=5% and >5% of total capital tax assets)			
Other (items listed individually >5% of total capital tax assets)			
99. Subtotal	\$	\$	\$
f. Statutory valuation allowance adjustment			
g. Nonadmitted			
h. Admitted capital deferred tax assets (2e99-2f-2g)			
i. Admitted deferred tax assets (2d+2h)	\$ 2,266,869	\$ 1,287,004	\$ 979,865

Deferred Tax Liabilities

	1	2	3
			(Col 1-2)
	2019	2018	Change
a. Ordinary:	•		
1. Investments	\$ 1,414	\$ 1,264	\$ 150
2. Fixed assets			
Deferred and uncollected premium			

		1	2		3 (Col 1-2)
		2019	2018		Change
Policyholder reserves					-
5. Other (items <=5% and >5% of total ordinary tax liabilities)					
Other (items listed individually >5% of total ordinary tax liabilities)				1	
99. Subtotal	\$	1,414	\$ 1,264	\$	150
b. Capital:	Ψ	.,	1,201	ĮΨ	100
1. Investments	\$	1,017,887	\$ 405,238	\$	612,649
2. Real estate					
3. Other (Items <=5% and >5% of total capital tax liabilities)					
Other (items listed individually >5% of total capital tax liabilities)			T	1	
99. Subtotal	\$	1,017,887	\$ 405,238	\$	612,649
c. Deferred tax liabilities (3a99+3b99)	\$	1,019,301	\$ 406,502	\$	612,799
Net Deferred Tax Assets/Liabilities (2i – 3c)	\$	1.247.568	\$ 880.502	\$	367.066

D. Reconciliation of Federal Income Tax Rate to Actual Effective Rate Among the more significant book to tax adjustments were the following:

	Amount	Effective Tax Rate (%)
Permanent Differences:		
Provision computed at statutory rate	\$ (76,485)	21.0%
Change in nonadmitted assets		%
Proration of tax exempt investment income	4,906	(1.3)%
Tax exempt income deduction		%
Dividends received deduction	(19,624)	5.4%
Disallowed travel and entertainment	10,117	(2.8)%
Other permanent differences	255,443	(70.1)%
Temporary Differences:		
Total ordinary DTAs		%
Total ordinary DTLs		%
Total capital DTAs		%
Total capital DTLs		%
Other:		
Statutory valuation allowance adjustment		%
Accrual adjustment – prior year	(214,573)	58.9%
Other	312,346	(85.8)%
Totals	\$ 272,130	(74.7)%
Federal and foreign income taxes incurred	511,586	(140.5)%
Realized capital gains (losses) tax	21,699	(6.0)%
Change in net deferred income taxes	(261,156)	71.7%
Total statutory income taxes	\$ 272,129	(74.7)%

E. Operating Loss Carry Forwards and Income Taxes Available for Recoupment

The amounts, origination dates and expiration dates of operating loss and tax credit carry forwards available for tax purposes:

Description (Operating Loss or Tax Credit Carry Forward)	Amounts	Origination Dates	Expiration Dates
None	\$		

2. The following is income tax expense for current year and proceeding years that is available for recoupment in the event of future net losses:

Year	Amounts		
2019	\$ 567,902		
2018	\$ 2,677,067		

3. The Company's aggregate amount of deposits admitted under Section 6603 of the Internal Revenue Service Code

F. Consolidated Federal Income Tax Return

The Company does not file a Consolidated Federal Income Tax Return.

G. Federal or Foreign Federal Income Tax Loss Contingencies:

The Company has no tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.

H. Repatriation Transition Tax (RTT) - RTT owed under the TCJA

The Company does not owe RTT.

I. Alternative Minimum Tax Credit

The Company does not have any AMT credits.

Note 10 - Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

Α. Nature of the Relationship Involved

> The Company was formed on January 1, 1994. The Company's shareholders as of December 31, 2019 were Arkansas Blue Cross and Blue Shield (50%) and Baptist Medical System HMO, Inc. (50%). Effective October 1st, 2006, USAble Corporation, a wholly owned subsidiary of Arkansas Blue Cross and Blue Shield (ABCBS), sold its ownership interest in HMO Partners, Inc. to ABCBS for \$27,143,396.

B & C. Transactions/Dollar Amounts of Transactions

> The Company, d/b/a Health Advantage, serves as the Third Party Administrator for the self-insured employee groups of ABCBS and Baptist Health. All receivables and payables dealing with their employee groups are classified under Uninsured Plans. At December 31, 2019, receivables of \$2,172,915 and \$2,601,234 were due respectively from Baptist Health and ABCBS. Payable balances of \$600,000 and \$1,487,035 are recorded respectively for Baptist Health and ABCBS.

D. Amounts Due From or To Related Parties

At December 31, 2019 the Company reported the following amounts due to Affiliates:

Arkansas Blue Cross and Blue Shield \$11,965,015 **USAble Life** 52,235 \$12,017,250 Total

E. Guarantees or Undertakings

N/A

F. Material Management or Service Contracts and Cost-Sharing Arrangements

> The Company reimburses Arkansas Blue Cross and Blue Shield for various administrative, employee benefit and marketing shared expenses, which are provided to the Company. These expenses are allocated to the Company in accordance with generally accepted accounting principles. In addition, the Company leases office space from Arkansas Blue Cross and Blue Shield.

G. Nature of the Control Relationship

Amount Deducted from the Value of Upstream Intermediate Entity or Ultimate Parent Owned

N/A

Investments in SCA that Exceed 10% of Admitted Assets

N/A

J. Investments in Impaired SCAs

N/A

Investment in Foreign Insurance Subsidiary

Investment in Downstream Noninsurance Holding Company L.

All SCA Investments M.

N/A

N. Investment in Insurance SCAs

N/A

O. SCA or SSAP 48 Entity Loss Tracking

N/A

Note 11 - Debt

A. Debt Including Capital Notes

As of December 31, 2019, the Company has no capital notes. As of December 31, 2019, the Company's liability for borrowed money was zero (\$-0-).

B. FHLB (Federal Home Loan Bank) Agreements

As of December 31, 2019, the Company has no FHLB agreements.

Note 12 - Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

N/A

B. Investment Policies and Strategies

N/A

C. Fair Value of Plan Assets

N/A

D. Basis Used to Determine Expected Long-Term Rate-of-Return

N/A

E. Defined Contribution Plans

The Company offers an optional 401(k) plan to all eligible employees. The employee has the option of deferring up to 50% of his or her salary. The Company matches the amount deferred by the employee based upon years of service from a minimum of 50% to a maximum of 100% of a 6% contribution.

Effective July 1, 1998, the plan was amended to establish a non-contributory, defined contribution portion of the plan known as 401(k) Plu\$. Employees are not required to participate in the original defined contribution plan in order to receive benefits under the 401(k) Plu\$ portion of the plan. At the end of each calendar year, employees will receive and annual 401(k) Plu\$ contribution equal to a minimum of 2% of the employee's annual earnings. The determination of the percentage to be used in calculating the contribution is based upon annually established net income targets. For 2019, 6% has been used to calculate the Company's contribution of \$519,871.

All funds under the 401(k) Plu\$ portions of the plan are held by an outside trustee.

F. Multiemployer Plans

The Company does not participate in multiemployer plans.

G. Consolidated/Holding Company Plans

N/A

H. Postemployment Benefits and Compensated Absences

The Company does not offer a postretirement benefit plan.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

N/A

NOTES TO FINANCIAL STATEMENTS

(1) Number of Share and Par or State Value of Each Class

> As of December 31, 2019, the Company had 1,000,000 common stock shares authorized, issued and outstanding at \$.01 par value.

(2) Dividend Rate, Liquidation Value and Redemption Schedule of Preferred Stock Issues

The Company has no preferred stock outstanding.

(3) **Dividend Restrictions**

Dividends are paid based on earned surplus and cannot fall below state net worth requirements.

(4) Dates and Amounts of Dividends Paid

> Dividends on Company stock are paid as declared by its Board of Directors. Ordinary dividends were paid on March 13, 2019 in the amount of \$640,968.

(5) Profits that may be Paid as Ordinary Dividends to Stockholders

All unassigned surplus is being held for the stockholder.

(6) Restrictions Placed on Unassigned Funds (Surplus)

> As of December 31, 2019, the Company held no stock for special purposes such as employee stock options or conversion of preferred stock.

(7) Amount of Advances to Surplus not Repaid

The Company does not have any advances to surplus.

(8) Amount of Stock Held for Special Purposes

N/A

(9) Reasons for Changes in Balance of Special Surplus Funds from Prior Period

The Company has no special surplus funds.

- (10)The Portion of Unassigned Funds (Surplus) Represented or Reduced by Unrealized Gains and Losses is: \$2,605,524.
- The Reporting Entity Issued the Following Surplus Debentures or Similar Obligations (11)

The Company has no surplus notes.

(12)The impact of any restatement due to prior quasi-reorganizations is as follows

The Company was not involved in a quasi-reorganization

(13)Effective Date of Quasi-Reorganization for a Period of Ten Years Following Reorganization

The Company was not involved in a quasi-reorganization.

Note 14 - Liabilities, Contingencies and Assessments

Contingent Commitments

None

B. Assessments

None

C. Gain Contingencies

None

D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits - Total SSAP 97 and SSAP 48 Contingent Liabilities

None

E. Joint and Several Liabilities

None

F. All Other Contingencies

Various lawsuits against the Company have arisen in the course of the Company's business. Contingent liabilities arising from litigation, income taxes and other matters are not considered material in relation to the financial position of the Company. The Company has no asset that it considers to be impaired.

Note 15 - Leases

A. Lessee Operating Lease

The Company does not have any items related to lessee leasing arrangements at this time.

B. Lessor Leases

N/A

Note 16 - Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit Risk

The Company does not have any off-balance sheet risk.

1. The table below summarizes the face amount of the Company's financial instruments with off-balance sheet risk:

N/A

2. Nature and Terms of Off-Balance Sheet Risk

N/A

3. Amount of Loss if any Party to the Financial Instrument Failed

N/A

4. Collateral or Other Security Required to Support Financial Instrument

N/A

Note 17 - Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

The Company did not have any transfers of Receivables reported as Sales.

B. Transfer and Servicing of Financial Assets

The Company did not have any transfers or servings of Financial Assets.

C. Wash Sales

The Company did not have any Wash Sales.

Note 18 - Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. ASO Plans

The gain from operations from Administrative Services Only (ASO) uninsured plans and he uninsured portion of partially insured plans was as follows during 2019:

		ASO Uninsured Plans	Uninsured Portion of Partially Insured Plans	Total ASO
a.	Net reimbursement for administrative expenses (including administrative fees) in excess of actual expenses	\$ (2,133,295)	\$	\$ (2,133,295)
b.	Total net other income or expenses (including interest paid to or received from plans)			
C.	Net gain or (loss) from operations	(2,133,295)		(2,133,295)
d.	Total claim payment volume	\$ 261,592,860	\$	\$ 261,592,860

B. ASC Plans

N/A

C. Medicare or Similarly Structured Cost Based Reimbursement Contract

N/A

Note 19 - Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

The Company does not currently have any direct premium written/produced by managing general agents/third party administrators.

Name and Address of Managing General Agent or	FEIN	Exclusive		Types of Authority	Total Direct Premiums Written/
Third Party Administrator	Number	Contract	Types of Business Written	Granted	Produced By
					\$
					\$
Total	XXX	XXX	XXX	XXX	

Note 20 - Fair Value Measurements

A. Fair Value Measurements

(1) Fair Value Measurements at Reporting Date

				Ne	et Asset Value	
Description for Each Type of Asset or Liability	(Level 1)	(Level 2)	(Level 3)	(NAV)		Total
Assets at Fair Value						
Other Invested Assets	\$	\$	\$	\$	11,470,781	\$ 11,470,781
Common Stock	\$ 4,928,626	\$ 2,065,056	\$	\$		\$ 6,993,681
Supplemental Savings Plan	\$ 591,733	\$	\$	\$		\$ 591,733
Total	\$ 5,520,358	\$ 2,065,056	\$	\$	11,470,781	\$ 19,056,195
Liabilities at Fair Value						
	\$	\$	\$	\$		\$
Total	\$	\$	\$	\$		\$

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

The Company does not have fair value measurements in Level 3.

(3) Policies when Transfers Between Levels are Recognized

The Company does not have any transfers between levels of fair value measurement.

(4) Description of Valuation Techniques and Inputs Used in Fair Value Measurement

As of December 31, 2019, the reported fair value of the reporting entities investments in Level 2 common stock was \$2,065,056. These securities are foreign common stock. To measure their fair value, the reporting entity used current market prices in U.S. dollars.

(5) Fair Value Disclosures

The company does not have any derivative assets and liabilities.

B. Fair Value Reporting under SSAP 100 and Other Accounting Pronouncements

N/A

C. Fair Value Level

	A	ggregate Fair						Ne	t Asset Value	Not Practicable
Type of Financial Instrument		Value	A	dmitted Assets	(Level 1)	(Level 2)	(Level 3)		(NAV)	(Carrying Value)
Other Invested Assets	\$	11,470,781	\$		\$	\$	\$	\$	11,470,781	\$
Bonds	\$	54,037,018	\$	54,037,018	\$	\$	\$	\$		\$
Common Stock	\$	6,993,681	\$		\$ 4,928,626	\$ 2,065,056	\$	\$		\$
Supplemental Savings Plan	\$	591,733	\$	591,733	\$ 591,733	\$ •	\$	\$	•	\$

D. Not Practicable to Estimate Fair Value

The Company does not have any of these securities at this time.

- E. NAV Practical Expedient Investments
 - 1. Martingale Investment Trust Series 1 Low Volatility Large Cap+

This strategy seeks to meet or exceed equity market returns while realizing significantly less volatility. This investment focuses on identifying and investing in low risk companies with sound fundamental properties. The portfolio is considered to be a low risk portfolio with broad, stable sector diversification. The fund contains 214 individual holdings as of 12/31/2019 with the top 10% of all holdings representing 13.0% of all fund holdings. Overall, the risk target of this portfolio is to perform with 70%-80% of the overall market volatility of the Russell 1000 Index.

The fund is able to be liquidated on a monthly basis. Because the underlying portfolio contains assets that are part of the Russell 1000 Index, it is very probable that the fund would not liquidate at the NAV of a prior month. It is possible the fund could be liquidated at a higher or lower price depending on overall market actions.

Barings U.S. Loan Fund Series - Tranche A

The Barings investment process is a focused and detailed fundamental bottom-up due diligence. The firm's investment philosophy is based on the belief that long-term, risk-adjusted returns can best be achieved through active portfolio management coupled with strong fundamental credit underwriting with the goal of minimizing principal losses. The firm takes a credit-intensive approach when selecting assets that seeks to determine where favorable value exists within companies on a relative basis to other investment alternatives.

The average number of loans in the portfolio is 183 at the end of the fourth quarter 2019, with 13.3% in the top ten holdings. The portfolio is diversified across eleven sectors, with six sectors containing more than 10% of all holdings. Average annualized default since inception is 0.5%, while the historical average is 2.9%.

The fund has daily liquidity but a 30 calendar day prior to withdraw notice is necessary. As of 12/31/2019, there are \$1.2 Billion assets in the Commingled Fund.

- 2. Not Applicable (The investments can be redeemed on a monthly basis.)
- 3. Not Applicable (There is no required capital commitment for the investments in Martingale or Barings)
- 4. Redemption of shares of either holding are processed on a monthly basis at prevailing market NAV.
- 5. Not Applicable
- 6. Not Applicable (There are no restrictions to viewing the investments of the Martingale Investment Trust Series 1 Low Volatility Large Cap+ or the Barings U.S. Loan Fund Series Tranche A. The holdings are provided to the Investor in each of the fund's annual reports, and can be requested at any month end closing.)
- 7. Not Applicable (The investor has not made a decision to redeem shares of the Martingale Investment Trust Series 1 Low Volatility Large Cap+ or the Barings U.S. Loan Fund Series Tranche A at this time.)

Note 21 - Other Items

A. Unusual or Infrequent Items

The Company had no unusual or infrequent items as of December 31, 2019.

B. Troubled Debt Restructuring Debtors

The Company had no troubled debt restructuring as of December 31, 2019.

C. Other Disclosures

The Company has no other disclosures as of December 31, 2019.

D. Business Interruption Insurance Recoveries

The Company has no business interruption insurance recoveries.

E. State Transferable and Non-Transferable Tax Credits

The Company has no state transferable tax credits

- F. Subprime Mortgage Related Risk Exposure
 - The Company does not engage in sub-prime residential mortgage lending. The Company holds direct investments in collateralized debt obligations that are backed by sub-prime mortgages. The Company's exposure to sub-prime mortgages is limited by its investment guidelines.

The book adjusted carrying value of investments with direct sub-prime mortgage risk exposure is \$67,203. This investment represents .12% of the Company's long-term bond holdings of \$54,037,018.

- The Company has direct exposure through investments as described in the response to question #1.
- 3) The Company has no material direct exposure through other investments.
- 4) The Company has no underwriting exposure to sub-prime mortgage risk through Mortgage Guaranty or Financial Guaranty Insurance Coverage.
- G. Retained Assets

The Company has no retained assets.

H. Insurance-Linked Securities (ILS) Contracts

The Company has no insurance-linked securities (ILS) contracts.

l. The Amount that Could be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or has Otherwise Obtained Rights to Control the

The Company has no life insurance where the reporting entity is owner and beneficiary or has otherwise obtained rights to control the policy.

Note 22 - Events Subsequent

Subsequent events have been considered through for these statutory financial statements which are to be issued on .

Α.	Did the reporting entity write accident and health insurance premium that is subject to Section 9010
	of the Endard Affordable Care Act (VEC/NO)2

74.	of the Federal Affordable Care Act (YES/NO)?		Yes [X] No []
		2019	2018
B.	ACA fee assessment payable for the upcoming year	\$ 5,400,000	\$
С	ACA fee assessment paid	\$	\$ 3,680,568
D.	Premium written subject to ACA 9010 assessment	\$ 211,916,340	\$
E.	Total adjusted capital before surplus adjustment (Five-Year Historical Line 14)	\$ 68,543,030	
F.	Total adjusted capital after surplus adjustment (Five-Year Historical Line 14 minus 22B above)	\$ 63,143,030	
G.	Authorized control level (Five-Year Historical Line 15)	\$ 8,130,114	

Would reporting the ACA assessment as of December 31, 2019 have triggered an RBC action level (YES/NO)? Η.

Yes [] No [X]

Note 23 - Reinsurance

Ceded Reinsurance Report

- (1) Are any of the reinsurers listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company? Yes [] No [X] If yes, give full details.
- (2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or any other person not primarily engaged in the insurance business? Yes [] No [X] If yes, give full details.

Section 2 - Ceded Reinsurance Report - Part A

- (1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits? Yes [] No [X]
 - a. If yes, what is the estimated amount of the aggregate reduction in surplus of a unilateral cancellation by the reinsurer as of the date of this statement, for those agreements in which cancellation results in a net obligation of the reporting entity to the reinsurer, and for which such obligation is not presently accrued? Where necessary, the reporting entity may consider the current or anticipated experience of the business reinsured in making this estimate. §
 - b. What is the total amount of reinsurance credits taken, whether as an asset or as a reduction of liability, for these agreements in this statement? §
- (2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies? Yes [] No [X] If yes, give full details.

Section 3 - Ceded Reinsurance Report - Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business reinsured in making this estimate. §
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement? Yes [] No [X] If yes, what is the amount of reinsurance credits, whether an asset or a reduction of liability, taken for such new agreements or amendments? \$\frac{1}{2}\$
- B. Uncollectible Reinsurance

The Company did not have any uncollectible reinsurance written off during the year.

C. Commutation of Ceded Reinsurance

There was no commutation of reinsurance during the year.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

There was no certified reinsurer rating downgraded or status subject to revocation during the year.

Note 24 - Retrospectively Rated Contracts and Contracts Subject to Redetermination

A. Method Used to Estimate Accrued Retrospective Premium Adjustments

The company estimates accrued retrospective premium adjustments for its group health insurance business though a mathematical approach using an algorithm of the company's underwriting rules and experience rating practices.

The company also has health insurance business that is subject to a medical loss ratio pursuant to the Public Health Service Act.

B. Retrospective Premiums Recorded Through Written Premium or Adjustment to Earned Premium

The company records accrued retrospective premium as an adjustment to earned premium.

C. Amount and Percentage of Net Premiums Written Subject to Retrospective Rating Features

The amount of net premiums written by the company at December 31, 2019 that are subject to retrospective rating features was \$211,916,338 that represented 100% of the total net premium written. No other net premiums written by the company are subject to retrospective rating features.

D. Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act

	1	2	3	4	5
		Small Group	Large Group	Other Categories	
	Individual	Employer	Employer	with Rebates	Total
Prior Reporting Year					
(1) Medical loss ratio rebates incurred	\$	\$	\$	\$ 73,946	\$ 73,946
(2) Medical loss ratio rebates paid	\$	\$	\$	\$	\$
(3) Medical loss ratio rebates unpaid	\$	\$	\$	\$ 188,258	\$ 188,258
(4) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	\$
(5) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	\$ 143,701
(6) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	\$ 44,557
Current Reporting Year-to-Date					
(7) Medical loss ratio rebates incurred	\$	\$	\$	\$ (188,258)	\$ (188,258)
(8) Medical loss ratio rebates paid	\$	\$	\$	\$	\$
(9) Medical loss ratio rebates unpaid	\$	\$	\$	\$	\$
(10) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	\$
(11) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	\$
(12) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	\$

E. Risk-Sharing Provisions of the Affordable Care Act

(1) Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions

Yes[X] No[]

(2) Impact of Risk-Sharing Provisions of the Affordable Care Act on admitted assets, liabilities and revenue for the current year:

a. Pe	rmanent ACA Risk Adjustment Program	AMOUNT		
Assets				
1.	Premium adjustments receivable due to ACA Risk Adjustment (including high-risk pool payments)	\$	442,798	
Liabilities	3			
2.	Risk adjustment user fees payable for ACA Risk Adjustment	\$		
3.	Premium adjustments payable due to ACA Risk Adjustment (including high-risk pool premium)	\$	(77,793)	
Operatio	ns (Revenue & Expenses)			
4.	Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk			
	Adjustment	\$	707,138	
5.	Reported in expenses as ACA Risk Adjustment user fees (incurred/paid)	\$	5,603	

b. Tra	nsitional ACA Reinsurance Program	AMOUNT
Assets		
1.	Amounts recoverable for claims paid due to ACA Reinsurance	\$
2.	Amounts recoverable for claims unpaid due to ACA Reinsurance (contra liability)	\$
3.	Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	\$
Liabilities		
4.	Liabilities for contributions payable due to ACA Reinsurance – not reported as ceded premium	\$
5.	Ceded reinsurance premiums payable due to ACA Reinsurance	\$
6.	Liabilities for amounts held under uninsured plans contributions for ACA Reinsurance	\$
Operation	ns (Revenue & Expenses)	·
7.	Ceded reinsurance premiums due to ACA Reinsurance	\$
8.	Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	\$
9.	ACA Reinsurance contributions – not reported as ceded premium	\$

C.	Tem	porary ACA Risk Corridors Program	AMOUNT						
Asse	Assets								
	1.	Accrued retrospective premium due to ACA Risk Corridors Liabilities	\$						
	2.	Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors	\$						
Oper	ration	s (Revenue & Expenses)							
	3.	Effect of ACA Risk Corridors on net premium income (paid/received)	\$						
	4.	Effect of ACA Risk Corridors on change in reserves for rate credits	\$						

(3) Roll forward of prior year ACA Risk Sharing Provisions for the following asset (gross of any nonadmission) and liability balances along with the reasons for adjustments to prior year balance:

Accrued During Received or Paid as of Prior Year Prior Year To Prior Year Unsettled Balances as of the Reporting Date

Output During Received or Paid as of Prior Year Prior Year To Prior Year Cumulative Cumulative

		Business Before the Prior	Dec. 31 of Year	the Prior	Written Dec. 31 of Year	Accrued Less Payments (Col. 1-3)	Accrued Less Payments (Col. 2-4)	Balances	Balances		Balance from Prior Years (Col. 1-3+7)	Balance from Prior Years (Col. 2-4+8)
		1	2	3	4	5	6	7	8		0	10
a.	Permanent ACA Risk Adjustment Program	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)		Receivable	(Payable)
	Premium adjustments receivable (including high-risk pool payments)	\$ 146,650	\$	\$ 461,789	\$	\$ (315,139)	\$	\$	\$	Α	\$ (315,139)	\$
	Premium adjustments (payable) (including high-risk pool premium)		78,310		51,317		26,993			В		26,993
	3. Subtotal ACA Permanent Risk Adjustment	\$ 146,650	\$ 78,310	\$ 461,789	\$ 51,317	\$ (315,139)	\$ 26,993	¢	\$		\$ (315,139)	\$ 26,002
b.	Program Transitional ACA Reinsurance Program	μ 140,03U	\$ 78,310	<u> ψ 401,769</u>	\$ 51,317	\$ (315,139)	<u> </u>	\$	ĮΨ	<u> </u>	\$ (315,139)	\$ 26,993
	Amounts recoverable for claims paid Amounts	\$	\$	\$	\$	\$	\$	\$	\$	С	\$	\$
	recoverable for claims unpaid (contra liability)									D		
	Amounts receivable relating to uninsured plans									E		
	Liabilities for contributions payable due to ACA Reinsurance – not reported as											
	5. Ceded reinsurance									F		
	premiums payable 6. Liability for									G		
	amounts held under uninsured plans									Н		
	7. Subtotal ACA Transitional Reinsurance Program	\$	\$	\$	\$	\$	\$	\$	\$		\$	\$
C.	Temporary ACA Risk Corridors Program		T	T	I	1	T				1	
	Accrued retrospective premium	\$	\$	\$	\$	\$	\$	\$	\$	ı	\$	\$
	Reserve for rate credits or policy experience rating refunds									J		
	Subtotal ACA Risk Corridors Program	\$	\$	\$	\$	\$	\$	\$	\$		\$	\$
d.	Total for ACA Risk-Sharing Provisions	\$ 146,650	\$ 78,310	\$ 461,789	\$ 51,317	\$ (315,139)	\$ 26,993	\$	\$		\$ (315,139)	\$ 26,993

Explanations of Adjustments

A. B. C. D. E. F. G. H. I. J.

(4) Roll-Forward of Risk Corridors Asset and Liability Balances by Program Benefit Year

			Differences		Adjustments		Unsettled Balances as of the Reporting Date			
	Accrued During the Prior Year on Business	Received or Paid as of the Current Year on	Prior Year Accrued Less	Prior Year Accrued Less	To Prior Year Balances	To Prior Year Balances	Cumulative Balance from	Cumulative Balance from		
	Written Before	Business Written	71001000 2000	71001404 2000	Buildinoo	Balanooo	Dalarioo Irom	Balarioo iroini		

	Dec. 31 of the Prior Year			Before Dec. 31 of the Prior Year		Payments (Col. 2-4)				Prior Years (Col. 1-3+7)	Prior Years (Col. 2-4+8)
Risk Corridors	1	2	3	4	5	6	7	8		9	10
Program Year	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)		Receivable	(Payable)
a. 2014											
1. Accrued											
retrospective			_							_	
	\$	\$	\$	\$	\$	\$	\$	\$	Α	\$	\$
Reserve for rate credits for policy											
experience											
	\$	\$	\$	\$	\$	\$	\$	\$	В	\$	\$
b. 2015	·	•	1 *		1.*	1,4	17	1.*			1.*
1. Accrued											
retrospective											
	\$	\$	\$	\$	\$	\$	\$	\$	С	\$	\$
Reserve for rate											
credits for policy											
experience		_	_		_	_			_		
U	\$	\$	\$	\$	\$	\$	\$	\$	D	\$	\$
c. 2016			ı		1	T	Г	1			1
1. Accrued											
retrospective	r.	œ.	œ.	\$	•	\$	•		_	c	•
li i i	\$	\$	\$	\$	\$	Þ	Ф	\$	Е	\$	2
Reserve for rate											
credits or policy experience											
	\$	\$	\$	\$	\$	\$	\$	\$	F	\$	\$
d. Total for Risk	Ψ	Ψ	Ψ	Ψ	Ť	*	*	*		Ψ	¥
	\$	\$	\$	\$	s	\$	\$	\$		\$	\$

24E(4)d (Columns 1 through 10) should equal 24E(3)c3 (Column 1 through 10 respectively)

A. B. C. D. E.

(5) ACA Risk Corridors Receivable as of Reporting Date

,	7.67 Trisk Contacts Receivable as of Reporting Bate													
		1	2	3	4	5	5							
		Estimated Amount	Non-Accrued		Asset Balance									
		to be Filed or Final	Amounts for		(Gross of									
R	Risk Corridors Program	Amount Filed with	Impairment or	Amounts Received	Non-Admissions)	Non-Admitted	Net Admitted Asset							
	Year	CMS	Other Reasons	from CMS	(1-2-3)	Amount	(4–5)							
a.	2014	\$	\$	\$	\$	\$	\$							
b.	2015													
C.	2016													
d.	Total (a+b+c)	\$	\$	\$	\$	\$	\$							

24E(5)d (Column 4) should equal 24E(3)c1 (Column 9)

24E(5)d (Column 6) should equal 24E(2)c1

Note 25 – Change in Incurred Losses and Loss Adjustment Expenses

12/31/18 Reserves 23,565,491

2018 Claims paid in 2019 (22,362,746)

Net **1,202,745**

2018 Reserves Remaining 203,164

Favorable Development ____999,581

Note 26 - Intercompany Pooling Arrangements

A. Identification of the Lead Entity and all Affiliated Entities Participating in the Intercompany Pool

N/A

B. Description of Lines and Types of Business Subject to the Pooling Agreement

N/A

C. Description of Cessions to Non-Affiliated Reinsurance Subject to Pooling Agreement

N/A

D. Identification of all Pool Members that are Parties to Reinsurance Agreements with Non-Affiliated Reinsurers

N/A

E. Explanation of Discrepancies Between Entries of Pooled Business

N/A

F. Description of Intercompany Sharing

N/A

G. Amounts Due To/From Lead Entity and all Affiliated Entities Participating in the Intercompany Pool

N/A

Note 27 – Structured Settlements

Not Applicable

Note 28 - Health Care Receivables

A. Pharmaceutical Rebate Receivables

		Estimated Pharmacy	Р	harmacy Rebates as	Actual Rebates		Actual Rebates		Actual Rebates
		Rebates as Reported o	n	Billed or Otherwise	Received Within 90	R	eceived Within 91 to	ı	Received More than
Quarte	r	Financial Statements		Confirmed	Days of Billing		180 Days of Billing	1	80 Days After Billing
12/31/20	19	\$ 4,770,398	\$	-	\$ -	\$	-	\$	-
09/30/20	19	\$ 4,709,045	\$	4,747,560	\$ 3,709,248	\$	-	\$	-
06/30/20	19	\$ 4,588,506	\$	4,686,206	\$ 3,572,887	\$	754,844	\$	-
03/31/20	19	\$ 4,701,511	\$	4,588,506	\$ 3,656,300	\$	966,377	\$	(177,233)
12/31/20	18	\$ 4,434,792	\$	4,701,511	\$ 4,672,800	\$	486,700	\$	153,925
09/30/20	18	\$ 3,706,513	\$	4,249,670	\$ 3,164,477	\$	1,253,009	\$	23,548
06/30/20	18	\$ 3,744,736	\$	3,642,781	\$ 3,164,477	\$	682,775	\$	(768)
03/31/20	18	\$ 3,374,468	\$	3,761,488	\$ 3,188,570	\$	724,892	\$	5,195
12/31/20	17	\$ 2,919,385	\$	3,388,832	\$ 2,228,544	\$	739,329	\$	200,056
09/30/20	17	\$ 2,849,723	\$	2,924,376	\$ 1,823,558	\$	705,360	\$	498,072
06/30/20	17	\$ 2,697,711	\$	2,849,723	\$ 1,796,930	\$	700,341	\$	11,340
03/31/20	17	\$ 2,712,946	\$	2,697,712	\$ 1,806,308	\$	648,956	\$	1,217

B. Risk-Sharing Receivables

The Company has no risk sharing receivables.

Note 29 - Participating Policies

The Company has no participating contracts.

Note 30 – Premium Deficiency Reserves

The Company has no premium deficiency reserves as of December 31, 2019.

1. Liability carried for premium deficiency reserve: \$0

2. Date of most recent evaluation of this liability: <u>December 31, 2019</u>

3. Was anticipated investment income utilized in the calculation? Yes [X] No []

Note 31 – Anticipated Salvage and Subrogation

The Company has no estimates of anticipated salvage and subrogation as of December 31, 2019.

Statement as of December 31, 2019 of the **HMO Partners, Inc GENERAL INTERROGATORIES**

PART 1 - COMMON INTERROGATORIES GENERAL

1.1		porting entity a member of an Insurance Holding Company System consisting of two complete Schedule Y, Parts 1, 1A and 2.	or more affiliated persons, one or more of which is an insu	irer?	Ye	s[X]] No []
1.2	If yes, did official of similar to System F	d the reporting entity register and file with its domiciliary State Insurance Commissione in the state of domicile of the principal insurer in the Holding Company System, a regist the standards adopted by the National Association of Insurance Commissioners (NA Regulatory Act and model regulations pertaining thereto, or is the reporting entity subjuitally similar to those required by such Act and regulations?	ration statement providing disclosure substantially IC) in its Model Insurance Holding Company	Yes [X] No	[]	N/A []
1.3	State reg	gulating? <u>Arkansas</u>					
1.4		porting entity publicly traded or a member of publicly traded group?			Yes	[]	No [X]
1.5		ponse to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the					
2.1	reporting	change been made during the year of this statement in the charter, by-laws, articles of entity? Ite of change:	of incorporation, or deed of settlement of the		Yes	[]	No [X]
3.1	•	of what date the latest financial examination of the reporting entity was made or is bei	ing made.		12/3	1/2017	 7
3.2	State the	e as of date that the latest financial examination report became available from either the should be the date of the examined balance sheet and not the date the report was c	ne state of domicile or the reporting entity.			1/2017	
3.3		of what date the latest financial examination report became available to other states of thing entity. This is the release date or completion date of the examination report and			06/28	8/2019	9
3.4	•	department or departments? s Insurance Department					
3.5	Have all	s mourance bepartment. financial statement adjustments within the latest financial examination report been ac nt filed with departments?	counted for in a subsequent financial	Yes[]	No [1	N/A [X]
3.6		of the recommendations within the latest financial examination report been complied	with?	Yes [X	•	[]	N/A []
4.1	thereof u (more the	ne period covered by this statement, did any agent, broker, sales representative, non- inder common control (other than salaried employees of the reporting entity) receive c an 20 percent of any major line of business measured on direct premiums) of:					
	4.11	sales of new business?			Yes		No [X]
	4.12	renewals?			Yes	[]	No [X]
4.2		ne period covered by this statement, did any sales/service organization owned in whole credit or commissions for or control a substantial part (more than 20 percent of any materials of new business?			Yes	1 1	No [X]
	4.22	renewals?			Yes		No [X]
5.1		reporting entity been a party to a merger or consolidation during the period covered by	v this statement?		Yes		No [X]
•		swer is YES, complete and file the merger history data file with the NAIC.	, and state				[//]
5.2		ovide the name of entity, NAIC company code, and state of domicile (use two letter stathe merger or consolidation.	ate abbreviation) for any entity that has ceased to exist a	s a			
		1			2		3
		Name of Entity		Co	NAIC ompany Code		State of Domicile
6.1		reporting entity had any Certificates of Authority, licenses or registrations (including co overnmental entity during the reporting period?	rporate registration, if applicable) suspended or revoked		Yes	[]	No [X]
6.2	If yes, given	ve full information:					
7.1 7.2	Does any	y foreign (non-United States) person or entity directly or indirectly control 10% or more	e of the reporting entity?		Yes	[]	No [X]
-	7.21	State the percentage of foreign control					%
	7.22	State the nationality(s) of the foreign person(s) or entity(s); or if the entity is a mutual	al or reciprocal, the nationality of its manager or				
		attorney-in-fact and identify the type of entity(s) (e.g., individual, corporation, govern	nment, manager or attorney-in-fact).				
		Nationality	Type of Entit	y			
8.1 8.2		mpany a subsidiary of a bank holding company regulated with the Federal Reserve B se to 8.1 is yes, please identify the name of the bank holding company.	oard?		Yes	[]	No [X]
8.3	Is the co	mpany affiliated with one or more banks, thrifts or securities firms?			Yes	[]	No [X]
8.4	If the res	ponse to 8.3 is yes, please provide below the names and locations (city and state of the y services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptrolle	er of the Currency (OCC), the Federal Deposit Insurance	ıncial	.00		No [X]
	Corporat	ion (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's	s primary federal regulator.	3 4	1	5	6
		Affiliate Name				DIC	SEC
9.		he name and address of the independent certified public accountant or accounting fire LP_Little Rock, Arkansas_	m retained to conduct the annual audit?	l			
10.1	Has the i	insurer been granted any exemptions to the prohibited non-audit services provided by ed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Ru		S	Yes	[]	No [X]
10.2		ponse to 10.1 is yes, provide information related to this exemption:	and Decedie Med Dec 1979 and 1				
10.3	for in Se	insurer been granted any exemptions related to other requirements of the Annual Fina ction 18A of the Model Regulation, or substantially similar state law or regulation?	andal Reporting Iviodel Regulation as allowed		Yes	[]	No [X]
	16.0	ponse to 10.3 is ves, provide information related to this exemption:					

Statement as of December 31, 2019 of the **HMO Partners, Inc GENERAL INTERROGATORIES**

PART 1 - COMMON INTERROGATORIES

10.5 10.6	Has the reporting entity established an Audif the response to 10.5 is no or n/a, please	Yes[X]	No []	N/A []		
11.	What is the name, address and affiliation (of the individual providing the statement of Victor Davis, Employee of Arkansas Blue		ant associated with an actuarial consulting firm)			
12.1	Does the reporting entity own any securities	estate indirectly?		Yes[]	No [X]	
	12.11 Name of real estate holding co12.12 Number of parcels involved				0	
	12.13 Total book/adjusted carrying va	lue		\$		0
12.2	If yes, provide explanation					
13. 13.1	FOR UNITED STATES BRANCHES OF A	ALIEN REPORTING ENTITIES ONLY: e year in the United States manager or the United States t	rustees of the reporting entity?			
13.2	Door this statement contain all husiness to	ansacted for the reporting entity through its United States	Proper on ricks wherever legated?		Yes[]	No[]
13.3	Have there been any changes made to an		Didition fishs wherever located:		Yes[]	No[]
13.4	If answer to (13.3) is yes, has the domicilia			Yes[]	No[]	N/A [X]
14.1	Are the senior officers (principal executive functions) of the reporting entity subject to	er or controller, or persons performing similar		Yes[X]	No[]	
	, , , , , , , , , , , , , , , , , , , ,	ding the ethical handling of actual or apparent conflicts of		os;	100[11]	110[]
		derstandable disclosure in the periodic reports required to	be filed by the reporting entity;			
	() 11 3	rnmental laws, rules and regulations; riolations to an appropriate person or persons identified in	the code; and			
	(e) Accountability for adherence to the		title code, and			
14.11	If the response to 14.1 is no, please explain	n:				
14.2	Has the code of ethics for senior manager	s heen amended?			Yes[]	No [X]
14.21	If the response to 14.2 is yes, provide infor				103[]	NO[X]
44.0	The control of the control of the control of	· · · · · · · · · · · · · · · · · · ·			V []	N. IVI
14.3 14.31	If the response to 14.3 is yes, provide the	peen waived for any of the specified officers?			Yes[]	No [X]
		, , , ,				
15.1	Is the reporting entity the beneficiary of a L Bank List?	etter of Credit that is unrelated to reinsurance where the i	issuing or confirming bank is not on the SVO		Yes []	No [X]
15.2		American Bankers Association (ABA) Routing Number an nstances in which the Letter of Credit is triggered.				
	1 American Bankers Association (ABA)	2	3 Circumstances That Can Trigger		4	
	Routing Number	Issuing or Confirming Bank Name	the Letter of Credit		Amount	
				\$		
		BOARD OF DIRECT				
16. 17.		of the reporting entity passed upon either by the Board of I permanent record of the proceedings of its Board of Direc			Yes[X] Yes[X]	No [] No []
18.	Has the reporting entity an established pro	cedure for disclosure to its Board of Directors or trustees	of any material interest or affiliation on the part		103[7]	NO[]
	of any of its officers, directors, trustees or r	esponsible employees that is in conflict or is likely to confl	lict with the official duties of such person?		Yes [X]	No []
		FINANCIAL				
19.		basis of accounting other than Statutory Accounting Prince	ciples (e.g., Generally Accepted Accounting Principles)?		Yes[]	No [X]
20.1	20.11 To directors or other officers	sive of Separate Accounts, exclusive of policy loans):		\$		0
	20.12 To stockholders not officers			\$		0
	20.13 Trustees, supreme or grand (Fi	raternal only)		\$		0
20.2		nd of year (inclusive of Separate Accounts, exclusive of p	olicy loans):			
	20.21 To directors or other officers			\$		0
	20.22 To stockholders not officers20.23 Trustees, supreme or grand (Figure 1)	raternal only)				0
21.1	Were any assets reported in this statemen	t subject to a contractual obligation to transfer to another p	party without the liability for such obligation			
0.4.0	being reporting in the statement?				Yes[]	No [X]
21.2	If yes, state the amount thereof at December 21.21 Rented from others	er 31 of the current year:		\$		0
	21.22 Borrowed from others			\$		0
	21.23 Leased from others			\$		0
	21.24 Other			\$		0
22.1		assessments as described in the Annual Statement Instru	actions other than guaranty fund or		Yes[X]	No []
22.2	quaranty association association				1 00 [A]	INO[]
	guaranty association assessments? If answer is yes:					
	•	djustment		\$	46	51,788
-L.L	If answer is yes: 22.21 Amount paid as losses or risk a 22.22 Amount paid as expenses	djustment		\$ \$	46	0
	If answer is yes: 22.21 Amount paid as losses or risk a 22.22 Amount paid as expenses 22.23 Other amounts paid	djustment nts due from parent, subsidiaries or affiliates on Page 2 of		\$ \$ \$	46	

Statement as of December 31, 2019 of the HMO Partners, Inc **GENERAL INTERROGATORIES**

PART 1 - COMMON INTERROGATORIES

23.2	ii yes, iii	dicate any amounts receivable from parent included i	n the Page 2 amount.		φ		U
			INVESTMENT				
24.01	Were all	the stocks, bonds and other securities owned Decentual possession of the reporting entity on said date (o	nber 31 of current year, over which the reporting ther than securities lending programs address	ng entity has exclusive control, sed in 24.03)?		Yes[X]	No []
24.02	If no, giv	re full and complete information, relating thereto:					
24.03		urity lending programs, provide a description of the pr il is carried on or off-balance sheet (an alternative is t					
24.04	Does the	e company's security lending program meet the requi	rements for a conforming program as outlined	in the Risk-Based Capital Instructions?	Yes[]	No[]	N/A [X]
24.05	If answe	er to 24.04 is yes, report amount of collateral for confe	orming programs.		\$		0
24.06	If answe	er to 24.04 is no, report amount of collateral for other	programs		\$		0
24.07		ur securities lending program require 102% (domesti	c securities) and 105% (foreign securities) from	n the counterparty at the outset	V 1 1	No. C. 1	NI/A 7 3/ 1
24.00	of the co	ontract? e reporting entity non-admit when the collateral receiv	and from the counterparty falls helpy 1000/ 2		Yes[] Yes[]	No[]	N/A [X]
24.08 24.09.		e reporting entity non-admit when the collateral receiver reporting entity or the reporting entity's securities lea	' '	na Aareement (MSLA) to	res[]	No[]	N/A [X]
24.00.		securities lending?	iding agent utilize the Musici Scounties Estici	ng / grooment (wob/ to	Yes[]	No []	N/A [X]
24.10	For the i	reporting entity's security lending program, state the a	mount of the following as of December 31 of t	he current year:			
	24.101	Total fair value of reinvested collateral assets reported	ed on Schedule DL, Parts 1 and 2:		\$		0
		Total book adjusted/carrying value of reinvested colla		1 and 2:	\$		0
		Total payable for securities lending reported on the I	,, ,		\$		0
25.1	of the re	by of the stocks, bonds or other assets of the reporting porting entity or has the reporting entity sold or transf is subject to Interrogatory 21.1 and 24.03.)				Yes[X]	No []
25.2		ate the amount thereof at December 31 of the curren	t year:				
	25.21	Subject to repurchase agreements			\$		0
	25.22	Subject to reverse repurchase agreements			\$		0
	25.23	Subject to dollar repurchase agreements			\$		0
	25.24	Subject to reverse dollar repurchase agreements			\$		0
	25.25	Placed under option agreements			\$		0
	25.26	Letter stock or securities restricted as sale – excludi	ng FHLB Capital Stock		\$		0
	25.27	FHLB Capital Stock			\$		0
	25.28	On deposit with states			\$	30	00,000
	25.29	On deposit with other regulatory bodies			\$		0
	25.30	Pledged as collateral – excluding collateral pledged			\$		0
	25.31	Pledged as collateral to FHLB – including assets ba	cking funding agreements		\$		0
05.0	25.32	Other			\$		0
25.3	For cale	gory (25.26) provide the following:		2		3	
		Nature of Restriction	Des	scription		Amount	1
					\$		
26.1 26.2	If yes, ha	e reporting entity have any hedging transactions repo as a comprehensive description of the hedging progra ach a description with this statement.		e?	Yes[]	Yes[] No[]	No [X] N/A [X]
Lines 2	6 2 throu	gh 26.5: FOR LIFE/FRATERNAL REPORTING EN	TITIES ONI V				
26.3		e reporting entity utilize derivatives to hedge variable		a results of interest rate sensitivity?		Yes[]	No []
26.4		sponse to 26.3 is yes, does the reporting entity utilize:	, ,	• • • • • • • • • • • • • • • • • • •			
	26.41	Special accounting provision of SSAP No. 108				Yes []	No []
	26.42	Permitted accounting practice				Yes []	No []
	26.43	Other accounting guidance				Yes []	No []
26.5		onding yes to 26.41 regarding utilizing the special acc		rting entity attests to the following:		Yes []	No []
		ne reporting entity has obtained explicit approval from					
		edging strategy subject to the special accounting proventuring provectuarial certification has been obtained which indicate					
		serves and provides the impact of the hedging strate					
	He	nancial Officer Certification has been obtained which edging Strategy within VM-21 and the Clearly Defined tual day-to-day risk mitigation efforts.					
27.1		by preferred stocks or bonds owned as of December 3	31 of the current year mandatorily convertible i	nto equity, or, at the option of the issuer.			
		ble into equity?	,	1 27 7		Yes[]	No [X]
27.2	•	ate the amount thereof at December 31 of the curren	•		\$		0
28.	offices, v	ig items in Schedule E-Part 3-Special Deposits, real evaults or safety deposit boxes, were all stocks, bonds	and other securities, owned throughout the cu	irrent year held pursuant to a			
		Il agreement with a qualified bank or trust company in al Functions, Custodial or Safekeeping Agreements o				Yes[X]	No []
	28.01	For agreements that comply with the requirements of				[//]	
		Name of Cur	tadian(a)	2 Custodian's A			
		US Bank Institutional Trust and Custody	ιυαιαΠ(3 <i>)</i>	Custodian's Ad St. Louis. MO	iu1692		
	28.02	For all agreements that do not comply with the requi	rements of the NAIC Financial Condition Evol				
	20.02	location and a complete explanation	Temente of the typic i manual continuel Exal	minoro manaboon, provide the halle,			

29.1

29.2

29.3

30.

30.4

31.1 31.2

31.3

33.

Statement as of December 31, 2019 of the **HMO Partners, Inc GENERAL INTERROGATORIES**

PART 1 - COMMON INTERROGATORIES

	1 Name(s)			2 Location(s)		Complete	3 e Explana	ation(s)			
	Have there been any changes, including nar If yes, give full and complete information rela	_			he current y			Yes [] No [
	1 Old Custodian			2 New Custodian		3 Date of Change	!	Re	4 ason		
1	Investment management – Identify all invest to make investment decisions on behalf of the note as such. ["that have access to the inv	e reporting e	entity. F	or assets that are managed internally							
		N	ame of l	1 Firm or Individual			2 Affiliation				
	Foundation Resource Management								J		
	Gray D. Dillard										
	Martingale Asset Management, LP								J		
	Barings, LLC								J		
	Pacific Investment Management Company	LLC							J		
:	28.0597 For those firms/individuals listed in (i.e. designated with a "U") manage			on 28.05, do any firms/individuals unaf the reporting entity's invested assets?	filiated with	the reporting entity			Yes[)	(] N	
2	28.0598 For firms/individuals unaffiliated wit the total assets under managemen	n the reporting aggregate t	ng entity to more	r (i.e. designated with a "U") listed in than 50% of the reporting entity's inverse.	ne table for sted assets	Question 28.05, doe ?	S		Yes[>	K] N	
	For those firms or individuals listed in the tab for the table below.	le for 28.05	with an	affiliation code of "A" (affiliated) or "U"	(unaffiliated	d), provide the inform	nation				
	1			2		3		4		5	
										nvestme	
								Registe		anagen Agreem	
	Central Registration Depository Number			Name of Firm or Individual	Legal Entity Ider	Legal Entity Identifier (LE			IMA) Fi		
	116359	Founda	tion Res	source Management	N/A		SEC	;	No		
	108526			et Management, LP		549300GXM5ZG	549300GXM5ZGZJXZ1Y74		;	NO	
	106006	Barings			ANDKRHQKPRF 05	ANDKRHQKPRRG4Q2KLR 05		, NFA	NO		
104559 Pacific In				ent Management Company LLC		549300KGPYQZ 8	XGMYYI	N3 SEC	;	NO	
change es, cor	reporting entity have any diversified mutual is Commission (SEC) in the Investment			ection 5 (b) (1)])? 2	to the Secu	irities and		Post W	Yes [
	CUSIP			Name of Mutual Fund				Book/A	djusted Value		
								\$			
	TOTAL							\$			
each	mutual fund listed in the table above, comple	te the follow	ving sch				2			4	
	Name of Mutual Fund (from above table)			2 Name of Significant Holdir of the Mutual Fund	ng	Amount o Book/Ad Value At	justed Ca	arrying	Date of	4 Valuatio	
	(**************************************					\$					
vide th	ne following information for all short-term and	long-term b	onds ar	nd all preferred stocks. Do not substitu	ute amortize	d value or statemen	t value fo	r fair value.			
				1 Statement (Admitted) Value		2 Fair Value		Excess of S Value (-),		alue ov	
.1	Bonds			\$ 60,508,273	\$	62,234,0)21			. <i>,</i> 1,725,74	
2	Preferred Stocks			\$ 0	\$	02,201,0		S		,, 20,, .	
3	Totals			\$ 60,508,273	\$	62,234,0)21	\$	1	,725,74	
air valu	the sources or methods utilized in determining pricing obtained, where applicable, from all Trust & Custody, custodian for investment	NAIC 4th Q	uarter 2			narket prices provide	ed by US	S Bank			
s the r	rate used to calculate fair value determined by wer to 31.1 is yes, does the reporting entity h	y a broker o	r custod	lian for any of the securities in Schedu	le D?	electronic			Yes[>	K] N	
oy) for	all brokers or custodians used as a pricing so wer to 31.2 is no, describe the reporting entit	ource?				5.504 51110			Yes [>	(] N	
closure	e of fair value for Schedule D: the filing requirements of the <i>Purposes and F</i>					wed?			Yes[)	() N	

- Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? 32.1 32.2 If no, list exceptions:
- By self-designating 5GI securities, the reporting entity is certifying the following elements for each self-designation 5GI security:

 a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security
 - Issuer or obligor is current on all contracted interest and principal payments.
 - The insurer has an actual expectation of ultimate payment of all contracted interest and principal.

Foley & Lardner LLP

38.1

38.2

Statement as of December 31, 2019 of the HMO Partners, Inc GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES

Yes[] No[X] Has the reporting entity self-designated 5GI securities? 34. By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: The security was purchased prior to January 1, 2018. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. b. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as an NRSRO which is c. shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. d Has the reporting entity self-designated PLGI securities? Yes[] No[X] 35 By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. b. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? Yes [] No [X] 36.1 506,366 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any? 36.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations and statistical or rating bureaus during the period covered by this statement Name **Amount Paid** BlueCross BlueShield Association 488 988 37.1 \$ 311,399 Amount of payments for legal expenses, if any? 37.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement. 2 **Amount Paid** Name

connection with matters before legislative bodies, officers or departments or government during the period covered by this statement.		
1		2
Name	Amo	ount Paid
BlueCross BlueShield Association	\$	35,565

Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of government, if any?

List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in

117.789

177,000

\$

Statement as of December 31, 2019 of the HMO Partners, Inc

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1	Does to	he reporting entity have any direct Medicare	Supplement Insurance	ce in force?				Yes[]	No [X]
1.2	If yes, i	indicate premium earned on U.S. business	only.				\$		0
1.3	What p	portion of Item (1.2) is not reported on the M	edicare Supplement Ir	nsurance Experience Exhibit?			\$		0
	1.31	Reason for excluding:							
1.4	Indica	ate amount of earned premium attributable t	o Canadian and/or Otl	ner Alien not included in Item ((1.2) above.		\$		0
1.5	Indica	ate total incurred claims on all Medicare Sup	plement insurance.				\$		0
1.6	Individ	ual policies:							
	Most c	urrent three years:							
	1.61	Total premium earned					\$		0
	1.62	Total incurred claims					\$		0
	1.63	Number of covered lives							0
	All yea	rs prior to most current three years:							
	1.64	Total premium earned					\$		0
	1.65	Total incurred claims					\$		0
	1.66	Number of covered lives							0
1.7	Group	policies:							
	Most c	urrent three years:							
	1.71	Total premium earned					\$		0
	1.72	Total incurred claims					\$		0
	1.73	Number of covered lives							0
	All yea	irs prior to most current three years:							
	1.74	Total premium earned					\$		0
	1.75	Total incurred claims					\$		0
	1.76	Number of covered lives							0
2.	Health	Test:							
				1		2			
		5	•	Current Year	•	Prior Year			
	2.1	Premium Numerator	\$	211,916,338	\$	226,790,781			
	2.2	Premium Denominator	\$	211,916,338	\$	226,790,781			
	2.3	Premium Ratio (2.1/2.2)		100.0%		100.0%			
	2.4	Reserve Numerator	\$	29,714,566	\$	27,482,338			
	2.5	Reserve Denominator	\$	29,849,961	\$	27,927,213			
	2.6	Reserve Ratio (2.4/2.5)		99.5%		98.4%			
3.1		e reporting entity received any endowment I if the earnings of the reporting entity permi		hospitals, physicians, dentists	s, or others that is	agreed will be returned when,		Yes[]	No [X]
3.2		give particulars:						100[]	no[n]
4.1		copies of all agreements stating the period a ith the appropriate regulatory agency?	and nature of hospitals	', physicians', and dentists' car	re offered to subs	cribers and dependents been		Yes[X]	No []
4.2		reviously filed, furnish herewith a copy(ies)	of such agreement(s).	Do these agreements include	e additional benefi	ts offered?		Yes[]	No [X]
5.1		he reporting entity have stop-loss reinsuran						Yes [X]	No []
5.2	If no, e								
5.3	Maxim	um retained risk (see instructions)							
5.3	Maxim	um retained risk (see instructions) Comprehensive Medical					\$		0
5.3							\$		0
5.3	5.31	Comprehensive Medical					<u> </u>		
5.3	5.31 5.32	Comprehensive Medical Medical Only					\$		0
5.3	5.315.325.33	Comprehensive Medical Medical Only Medicare Supplement					\$		0

7.1

Does the reporting entity set up its claim liability for provider services on a service date basis?

Statement as of December 31, 2019 of the HMO Partners, Inc **GENERAL INTERROGATORIES**

PART 2 – HEALTH INTERROGATORIES

Yes[X] No[]

7.2	If no, give details							
8.	Provide the following information regarding participating providers:							
	8.1 Number of providers at start of reporting year							17,795
	8.2 Number of providers at end of reporting year							18,783
9.1	Does the reporting entity have business subject to premium rate gua	rantees?					Yes []	No [X]
9.2	If yes, direct premium earned:						. 55 []	[]
	9.21 Business with rate guarantees with rate guarantees between	15-36 months	3			\$		0
	9.22 Business with rate guarantees over 36 months					\$		0
10.1	Does the reporting entity have Incentive Pool, Withhold or Bonus Arr	angements in	its provider co	ntracts?		*	Yes [X]	No []
10.2	If yes:	. 3						
	10.21 Maximum amount payable bonuses						3,4	181,558
	10.22 Amount actually paid for year bonuses							340,046
	10.23 Maximum amount payable withholds						6.6	657,045
	10.24 Amount actually paid for year withholds							118,378
11.1	Is the reporting entity organized as:							-,-
	11.12 A Medical Group/Staff Model,						Yes[]	No [X]
	11.13 An Individual Practice Association (IPA), or,						Yes[]	No [X]
	11.14 A Mixed Model (combination of above)?						Yes [X]	No []
11.2	Is the reporting entity subject to Statutory Minimum Capital and Surp	lus Requireme	ents?				Yes [X]	No []
	11.3 If yes, show the name of the state requiring such minimum	capital and su	rplus.					
	11.4 If yes, show the amount required.					\$		100,000
11.5	Is this amount included as part of a contingency reserve in stockhold	er's equity?					Yes[]	No [X]
11.6	If the amount is calculated, show the calculation							
12.	List service areas in which reporting entity is licensed to operate:							
	1							
	Name of Service Area Arkansas							
13.1	Do you act as a custodian for health savings accounts?						Yes[]	No [X]
13.2	If yes, please provide the amount of custodial funds held as of the re	porting date.				\$.00[]	0
13.3	Do you act as an administrator for health savings accounts?	,				*	Yes[]	No [X]
13.4	If yes, please provide the balance of the funds administered as of the	e reporting dat	te.			\$		0
14.1	Are any of the captive affiliates reported on Schedule S, Part 3, auth					Yes[]	No []	N/A [X]
14.2	If the answer to 14.1 is yes, please provide the following:							[]
	1	2	3	4	Asse	ts Supporting Reserve	Credit	
	Company	NAIC Company	Domiciliary	Reserve	5 Letters of	6 Trust	7	
	Name	Code	Jurisdiction	Credit	Credit	Agreements	Othe	er
		0		\$	\$	\$	\$	
15.	Provide the following for individual ordinary life insurance* policies (U	J.S. business	only) for the cu	rrent year (prior to re	einsurance assumed or	ceded).		J
	15.1 Direct Premium Written					\$		0
	15.2 Total Incurred Claims					\$		0
	15.3 Number of Covered Lives							0
	*Ordinal	ry Life Insura	nce Includes					
	Term (whether full underwriting, limi	ted underwriti	ng, jet issue, "s	short form app")				
	Whole Life (whether full underwriting	g, limited unde	erwriting, jet iss	ue, "short form app'	')			
	Variable Life (with or without second	dary guarante	e)					
	Universal Life (with or without secon		,					
	Variable Universal Life (with or with							
16.	Is the reporting entity licensed or charted, registered, qualified, eligib		-	ast two states?			Yes[]	No [X]
16.1	If no, does the reporting entity assume reinsurance business that cov	-			the state of domicile of	the	- •	
	reporting entity?						Yes[]	No [X]

Statement as of December 31, 2019 of the HMO Partners, Inc FIVE-YEAR HISTORICAL DATA

1146-1	EAR HISTOI				
	1 2019	2 2018	3 2017	4 2016	5 2015
Balance Sheet (Pages 2 and 3)					
Total admitted assets (Page 2, Line 28)	149,537,974	128,331,714	129,619,539	114,101,429	113,699,695
2. Total liabilities (Page 3, Line 24)	80,994,944	60,189,782	62,084,101	55,764,969	56,968,073
Statutory minimum capital and surplus requirement	100,000	100,000	100,000	100,000	100,000
4. Total capital and surplus (Page 3, Line 33)	68,543,030	68,141,934	67,535,438	58,336,460	56,731,623
Income Statement (Page 4)					
5. Total revenues (Line 8)	211,916,338	226,790,781	206,662,410	191,140,735	177,319,491
Total medical and hospital expenses (Line 18)	178,840,151	190,934,413	172,373,830	160,647,985	146,769,799
7. Claims adjustment expenses (Line 20)	12,046,965	9,181,040	7,501,887	7,985,047	4,942,930
Total administrative expenses (Line 21)	23,992,818	27,310,681	19,814,964	21,563,702	22,528,719
9. Net underwriting gain (loss) (Line 24)	(2,963,596)	(635,353)	6,971,730	944,001	3,078,043
10. Net investment gain (loss) (Line 27)	2,316,440	7,959,064	1,989,987	1,699,702	2,694,903
11. Total other income (Lines 28 plus 29)	261,242	221,690	324,342	257,206	443,669
12. Net income or (loss) (Line 32)	(897,500)	6,409,698	6,727,254	656,674	4,755,372
Cash Flow (Page 6)					
13. Net cash from operations (Line 11)	9,184,547	3,823,259	5,765,528	(3,091,553)	(2,170,291)
Risk-Based Capital Analysis					
14. Total adjusted capital	68,543,030	68,141,934	67,535,438	58,336,460	56,731,623
15. Authorized control level risk-based capital	8,130,114	8,495,660	7,487,825	7,062,655	6,373,918
Enrollment (Exhibit 1)					
16. Total members at end of period (Column 5, Line 7)	58,632	68,998	71,494	71,558	68,916
17. Total member months (Column 6, Line 7)	743,104	847,702	856,849	863,574	832,426
Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3, and 5) x 100.0					
18. Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19. Total hospital and medical plus other non-health (Line 18 plus Line 19).	84.4	84.2	83.4	84.0	82.8
20. Cost containment expenses	5.1	3.7	2.9	2.8	1.7
21. Other claims adjustment expenses	0.6	0.3	8.0	1.3	1.1
22. Total underwriting deductions (Line 23)	101.4	100.3	96.6	99.5	98.3
23. Total underwriting gain (loss) (Line 24)	(1.4)	(0.3)	3.4	0.5	1.7
Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24. Total claims incurred for prior years (Line 13, Col. 5)	26,037,263	22,911,004	21,527,564	20,914,897	15,854,765
25. Estimated liability of unpaid claims - [prior year (Line 13, Col. 6)]	27,482,068	24,827,638	17,961,171	21,599,029	18,183,349
Investments in Parent, Subsidiaries and Affiliates					
26. Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					
27. Affiliated preferred stocks (Sch D. Summary, Line 18, Col. 1)					
28. Affiliated common stocks (Sch D. Summary, Line 24, Col. 1)					
29. Affiliated short-term investments (subtotal included in Sch. DA, Verification, Column 5, Line 10)					
30. Affiliated mortgage loans on real estate					
31. All other affiliated					
32. Total of above Lines 26 to 31	0	0	0	0	0
33. Total investment in parent included in Lines 26 to 31 above					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3, Accounting Changes and Correction of Errors?

If no, please explain:

Yes [] No []

Statement as of December 31, 2019 of the **HMO Partners, Inc SCHEDULE T - PREMIUMS AND OTHER CONSIDERATIONS**


Allocated by States and Territories

		1 Direct Business Only								
		Active	2 Accident	3	4	5 Federal Employees Health	6	7 Property/	8 Total	9 Deposit-
	State, Etc.	Status (a)	& Health Premiums	Medicare Title XVIII	Medicaid Title XIX	Benefits Plan Premiums	Other Considerations	Casualty Premiums	Columns 2 Through 7	Type Contracts
1.	AlabamaAL	N							0	
2.	AlaskaAK	N							0	
	ArizonaAZ	N							0	
	ArkansasAR	L	258,879,809	46,693,462					305,573,270	
5.	CaliforniaCA	N							0	
ô. 7	ColoradoCO ConnecticutCT	N							0	
7. 8.	DelawareDE	N							0	
o. 9.	District of ColumbiaDC	N							0	
	FloridaFL	N							0	
	GeorgiaGA	N							0	
2.	HawaiiHI	N							0	
3.	ldahoID	N							0	
4.	IllinoisIL	N							0	
5.	IndianaIN	N							0	
6.	lowaIA	N							0	
7.	KansasKS	N							0	
8.	KentuckyKY	N							0	
9.	LouisianaLA	N							0	
0.	MaineME	N							0	
	MarylandMD	N							0	
22.	MassachusettsMA	N							0	
	MichiganMI	N							0	
24.	MinnesotaMN	N							0	
	MississippiMS	N							0	
26. 27	MissouriMO	N							0	
27.	MontanaMT NebraskaNE	N							0	
28. 29.	NevadaNV	N							0	
	New HampshireNH	N							0	
	New JerseyNJ	N				•••••			0	
	New MexicoNM	N							0	
	New YorkNY	N							0	
34.	North CarolinaNC	N							0	
	North DakotaND	N							0	
36.	OhioOH	N							0	
37.	OklahomaOK	N							0	
38.	OregonOR	N							0	
	PennsylvaniaPA								0	
	Rhode IslandRI	N							0	
	South CarolinaSC	N							0	
		N							0	
13.	TennesseeTN	N							0	
14.	TexasTX	N							0	
	UtahUT	N							0	
		N							0	
	VirginiaVA								0	
18.	WashingtonWA	N							0	
	West VirginiaWV	N							0	
	WisconsinWI								0	
	WyomingWY American SamoaAS	N							0	
	GuamGU	N							0	
	Puerto RicoPR	N							0	
	U.S. Virgin IslandsVI	N							0	
	Northern Mariana IslandsMP	N							0	
57.	CanadaCAN	N							0	
	Aggregate Other alienOT	XXX	0	0	0	0	0	0	0	
9.	Subtotal	XXX	258,879,809	46,693,462	0	0	0	0	305,573,270	
0.	Reporting entity contributions for			•						
	Employee Benefit Plans		2,717,038						2,717,038	
1.	Total (Direct Business)	XXX	261,596,847	46,693,462	0		0	0	308,290,309	
					AILS OF WRITE	-INS		1		
									0	
									0	
									0	
448	Summary of remaining write-ins for lin Total (Lines 58001 through 58003 + §	ne 58	0	0	0	0	0	0	0	
200.		วสรรม		0	0	0	0	J0	0	
999.	tive Status Counts:	00000,						•		

⁽b) Explanation of basis of allocation by states, premiums by state, etc.

SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATIONAL CHART



40

2019 ALPHABETICAL INDEX HEALTH ANNUAL STATEMENT BLANK

Analysis of Operations By Lines of Business Assets Cash Flow Exhibit 1 – Enrollment By Product Type for Health Business Only Exhibit 2 – Accident and Health Premiums Due and Unpaid Exhibit 3 – Health Care Receivables Exhibit 3 – Health Care Receivables Exhibit 4 – Claims Unpaid and Incentive Pool, Withhold and Bonus Exhibit 5 – Amounts Due From Parent, Subsidiaries and Affiliates Exhibit 7 – Part 1 – Summary of Transactions With Providers Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries Exhibit 6 – Furniture, Equipment and Supplies Owned Exhibit of Capital Gains (Losses) Exhibit of Nonadmitted Assets In Schedule DB – Part D – Section 2 Exhibit of Premiums, Enrollment and Utilization (State Page) Jurat Page 1 Schedule E – Part 1 – Cash Schedule E – Part 2 – Cash Equivalents Liabilities, Capital and Surplus Overflow Page For Write-ins	
Cash Flow6Schedule DA – Part 1Exhibit 1 – Enrollment By Product Type for Health Business Only17Schedule DA – Verification Between YearExhibit 2 – Accident and Health Premiums Due and Unpaid18Schedule DB – Part A – Section 1Exhibit 3 – Health Care Receivables19Schedule DB – Part A – Section 2Exhibit 3A – Health Care Receivables Collected and Accrued20Schedule DB – Part A – Verification Between Exhibit 4 – Claims Unpaid and Incentive Pool, Withhold and Bonus21Schedule DB – Part B – Section 1Exhibit 5 – Amounts Due From Parent, Subsidiaries and Affiliates22Schedule DB – Part B – Section 2Exhibit 6 – Amounts Due To Parent, Subsidiaries and Affiliates23Schedule DB – Part B – Verification Between Exhibit 7 – Part 1 – Summary of Transactions With Providers24Schedule DB – Part C – Section 1Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries24Schedule DB – Part C – Section 2Exhibit 6 – Furniture, Equipment and Supplies Owned25Schedule DB – Part D – Section 1Exhibit of Capital Gains (Losses)15Schedule DB – Part D – Section 2Exhibit of Nonadmitted Assets16Schedule DB – Part DExhibit of Premiums, Enrollment and Utilization (State Page)30Schedule DB – Part 1Five-Year Historical Data29Schedule DL – Part 1General Interrogatories27Schedule E – Part 1 – CashJurat Page1Schedule E – Part 2 – Cash EquivalentsNotes To Financial Statements26Schedule E – Pert 3 – Special Deposits	
Exhibit 1 – Enrollment By Product Type for Health Business Only Exhibit 2 – Accident and Health Premiums Due and Unpaid Exhibit 3 – Health Care Receivables 19 Schedule DB – Part A – Section 2 Exhibit 3A – Health Care Receivables Collected and Accrued Exhibit 3 – Health Care Receivables Collected and Accrued Exhibit 4 – Claims Unpaid and Incentive Pool, Withhold and Bonus Exhibit 5 – Amounts Due From Parent, Subsidiaries and Affiliates Exhibit 6 – Amounts Due To Parent, Subsidiaries and Affiliates Exhibit 7 – Part 1 – Summary of Transactions With Providers Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries Exhibit 8 – Furniture, Equipment and Supplies Owned Exhibit of Capital Gains (Losses) Exhibit of Nonadmitted Assets Exhibit of Premiums, Enrollment and Utilization (State Page) Jurat Page 1 Schedule E – Part 1 – Cash Equivalents Schedule E – Part 2 – Cash Equivalents Schedule E – Part 3 – Special Deposits Notes To Financial Statements 26 Schedule E – Part 3 – Special Deposits	
Exhibit 2 – Accident and Health Premiums Due and Unpaid Exhibit 3 – Health Care Receivables 19 Schedule DB – Part A – Section 2 Exhibit 3A – Health Care Receivables Collected and Accrued 20 Schedule DB – Part A – Verification Betwee Exhibit 4 – Claims Unpaid and Incentive Pool, Withhold and Bonus 21 Schedule DB – Part B – Section 1 Exhibit 5 – Amounts Due From Parent, Subsidiaries and Affiliates 22 Schedule DB – Part B – Section 2 Exhibit 6 – Amounts Due To Parent, Subsidiaries and Affiliates 23 Schedule DB – Part B – Verification Betwee Exhibit 7 – Part 1 – Summary of Transactions With Providers Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries Exhibit 8 – Furniture, Equipment and Supplies Owned Exhibit of Capital Gains (Losses) 15 Schedule DB – Part D – Section 1 Exhibit of Nonadmitted Assets 16 Schedule DB – Part E Exhibit of Premiums, Enrollment and Utilization (State Page) 30 Schedule DB – Part 1 Five-Year Historical Data 21 Schedule E – Part 2 – Cash Equivalents 22 Schedule E – Part 3 – Special Deposits Notes To Financial Statements 23 Schedule E – Part 3 – Special Deposits	E17
Exhibit 3 – Health Care Receivables Exhibit 3 – Health Care Receivables Collected and Accrued 20 Schedule DB – Part A – Verification Betwee Exhibit 4 – Claims Unpaid and Incentive Pool, Withhold and Bonus 21 Schedule DB – Part B – Section 1 Exhibit 5 – Amounts Due From Parent, Subsidiaries and Affiliates 22 Schedule DB – Part B – Section 2 Exhibit 6 – Amounts Due To Parent, Subsidiaries and Affiliates 23 Schedule DB – Part B – Verification Betwee Exhibit 7 – Part 1 – Summary of Transactions With Providers Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries Exhibit 8 – Furniture, Equipment and Supplies Owned Exhibit of Capital Gains (Losses) Exhibit of Nonadmitted Assets Exhibit of Nonadmitted Assets Exhibit of Premiums, Enrollment and Utilization (State Page) Jurat Page 10 Schedule E – Part 1 – Cash Equivalents Schedule E – Part 2 – Cash Equivalents Schedule E – Part 3 – Special Deposits Notes To Financial Statements 20 Schedule E – Part 3 – Special Deposits	rs SI10
Exhibit 3A – Health Care Receivables Collected and Accrued Exhibit 4 – Claims Unpaid and Incentive Pool, Withhold and Bonus 21 Schedule DB – Part B – Section 1 Exhibit 5 – Amounts Due From Parent, Subsidiaries and Affiliates 22 Schedule DB – Part B – Section 2 Exhibit 6 – Amounts Due To Parent, Subsidiaries and Affiliates 23 Schedule DB – Part B – Verification Between Exhibit 7 – Part 1 – Summary of Transactions With Providers Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries Exhibit 8 – Furniture, Equipment and Supplies Owned Exhibit of Capital Gains (Losses) Exhibit of Nonadmitted Assets Exhibit of Nonadmitted Assets Exhibit of Premiums, Enrollment and Utilization (State Page) Five-Year Historical Data General Interrogatories Direction 1 Exhibities, Capital and Surplus Schedule E – Part 2 – Cash Equivalents Notes To Financial Statements 20 Schedule D – Part 3 – Special Deposits Schedule E – Part 3 – Special Deposits	E18
Exhibit 4 – Claims Unpaid and Incentive Pool, Withhold and Bonus Exhibit 5 – Amounts Due From Parent, Subsidiaries and Affiliates Exhibit 6 – Amounts Due To Parent, Subsidiaries and Affiliates Exhibit 7 – Part 1 – Summary of Transactions With Providers Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries Exhibit 8 – Furniture, Equipment and Supplies Owned Exhibit 6 Capital Gains (Losses) Exhibit of Net Investment Income Exhibit of Nonadmitted Assets Exhibit of Premiums, Enrollment and Utilization (State Page) Five-Year Historical Data General Interrogatories Liabilities, Capital and Surplus Schedule E – Part 3 – Special Deposits Schedule E – Part 3 – Special Deposits Schedule E – Part 3 – Special Deposits	E19
Exhibit 5 – Amounts Due From Parent, Subsidiaries and Affiliates 22 Schedule DB – Part B – Section 2 Exhibit 6 – Amounts Due To Parent, Subsidiaries and Affiliates 23 Schedule DB – Part B – Verification Betwee Exhibit 7 – Part 1 – Summary of Transactions With Providers 24 Schedule DB – Part C – Section 1 Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries 24 Schedule DB – Part C – Section 2 Exhibit 8 – Furniture, Equipment and Supplies Owned 25 Schedule DB – Part D – Section 1 Exhibit of Capital Gains (Losses) 15 Schedule DB – Part D – Section 2 Exhibit of Net Investment Income 15 Schedule DB – Part E Exhibit of Nonadmitted Assets 16 Schedule DB – Verification Exhibit of Premiums, Enrollment and Utilization (State Page) 30 Schedule DL – Part 1 Five-Year Historical Data 29 Schedule DL – Part 2 General Interrogatories 27 Schedule E – Part 1 – Cash Jurat Page 1 Schedule E – Part 2 – Cash Equivalents Liabilities, Capital and Surplus 3 Schedule E – Part 3 – Special Deposits	een Years SI11
Exhibit 6 – Amounts Due To Parent, Subsidiaries and Affiliates Exhibit 7 – Part 1 – Summary of Transactions With Providers Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries Exhibit 8 – Furniture, Equipment and Supplies Owned Exhibit of Capital Gains (Losses) Exhibit of Nonadmitted Assets Exhibit of Nonadmitted Assets Exhibit of Premiums, Enrollment and Utilization (State Page) Five-Year Historical Data General Interrogatories Exhibities, Capital and Surplus Notes To Financial Statements 23 Schedule DB – Part B – Verification 1 Schedule DB – Part C – Section 2 Schedule DB – Part D – Section 1 Schedule DB – Part D – Section 2 Schedule DB – Part E Schedule DB – Part E Schedule DB – Part E Schedule DB – Part 1 Schedule DL – Part 1 Schedule DL – Part 1 Schedule E – Part 1 – Cash Schedule E – Part 2 – Cash Equivalents Schedule E – Part 3 – Special Deposits	E20
Exhibit 7 – Part 1 – Summary of Transactions With Providers Exhibit 7 – Part 2 – Summary of Transactions With Intermediaries Exhibit 8 – Furniture, Equipment and Supplies Owned Exhibit of Capital Gains (Losses) Exhibit of Net Investment Income Exhibit of Nonadmitted Assets Exhibit of Premiums, Enrollment and Utilization (State Page) Five-Year Historical Data General Interrogatories Liabilities, Capital and Surplus Notes To Financial Statements 24 Schedule DB – Part C – Section 2 Schedule DB – Part D – Section 1 Schedule DB – Part D – Section 2 Schedule DB – Part E Schedule DB – Part E Schedule DB – Verification 25 Schedule DL – Part 1 Schedule DL – Part 1 Schedule E – Part 1 – Cash Jurat Page 1 Schedule E – Part 2 – Cash Equivalents Schedule E – Part 3 – Special Deposits	E21
Exhibit 7 - Part 2 - Summary of Transactions With Intermediaries24Schedule DB - Part C - Section 2Exhibit 8 - Furniture, Equipment and Supplies Owned25Schedule DB - Part D - Section 1Exhibit of Capital Gains (Losses)15Schedule DB - Part D - Section 2Exhibit of Net Investment Income15Schedule DB - Part EExhibit of Nonadmitted Assets16Schedule DB - VerificationExhibit of Premiums, Enrollment and Utilization (State Page)30Schedule DL - Part 1Five-Year Historical Data29Schedule DL - Part 2General Interrogatories27Schedule E - Part 1 - CashJurat Page1Schedule E - Part 2 - Cash EquivalentsLiabilities, Capital and Surplus3Schedule E - Verification Between YearsNotes To Financial Statements26Schedule E - Part 3 - Special Deposits	een Years SI11
Exhibit 8 – Furniture, Equipment and Supplies Owned Exhibit of Capital Gains (Losses) Exhibit of Net Investment Income Exhibit of Nonadmitted Assets Exhibit of Premiums, Enrollment and Utilization (State Page) Exhibit of Nonadmitted Assets Exhibit of Net Investment Income Exhibit of Net	SI12
Exhibit of Capital Gains (Losses) Exhibit of Net Investment Income Exhibit of Nonadmitted Assets Exhibit of Nonadmitted Assets Exhibit of Premiums, Enrollment and Utilization (State Page) Five-Year Historical Data General Interrogatories Jurat Page 1 Schedule E - Part 2 - Cash Equivalents Liabilities, Capital and Surplus Notes To Financial Statements 1 Schedule E - Part 3 - Special Deposits	SI13
Exhibit of Net Investment Income Exhibit of Nonadmitted Assets 16 Schedule DB – Verification Exhibit of Premiums, Enrollment and Utilization (State Page) 30 Schedule DL – Part 1 Five-Year Historical Data 29 Schedule DL – Part 2 General Interrogatories 27 Schedule E – Part 1 – Cash Jurat Page 1 Schedule E – Part 2 – Cash Equivalents Liabilities, Capital and Surplus 3 Schedule E – Verification Between Years Notes To Financial Statements 26 Schedule E – Part 3 – Special Deposits	E22
Exhibit of Nonadmitted Assets Exhibit of Premiums, Enrollment and Utilization (State Page) Schedule DL - Part 1 Five-Year Historical Data 29 Schedule DL - Part 2 General Interrogatories 27 Schedule E - Part 1 - Cash Jurat Page 1 Schedule E - Part 2 - Cash Equivalents Liabilities, Capital and Surplus Notes To Financial Statements 26 Schedule E - Part 3 - Special Deposits	E23
Exhibit of Premiums, Enrollment and Utilization (State Page) Five-Year Historical Data 29 Schedule DL – Part 2 General Interrogatories 27 Schedule E – Part 1 – Cash Jurat Page 1 Schedule E – Part 2 – Cash Equivalents Liabilities, Capital and Surplus 3 Schedule E – Verification Between Years Notes To Financial Statements 26 Schedule E – Part 3 – Special Deposits	E24
Five-Year Historical Data 29 Schedule DL – Part 2 General Interrogatories 27 Schedule E – Part 1 – Cash Jurat Page 1 Schedule E – Part 2 – Cash Equivalents Liabilities, Capital and Surplus 3 Schedule E – Verification Between Years Notes To Financial Statements 26 Schedule E – Part 3 – Special Deposits	SI14
General Interrogatories 27 Schedule E – Part 1 – Cash Jurat Page 1 Schedule E – Part 2 – Cash Equivalents Liabilities, Capital and Surplus 3 Schedule E – Verification Between Years Notes To Financial Statements 26 Schedule E – Part 3 – Special Deposits	E25
Jurat Page1Schedule E – Part 2 – Cash EquivalentsLiabilities, Capital and Surplus3Schedule E – Verification Between YearsNotes To Financial Statements26Schedule E – Part 3 – Special Deposits	E26
Liabilities, Capital and Surplus 3 Schedule E – Verification Between Years Notes To Financial Statements 26 Schedule E – Part 3 – Special Deposits	E27
Notes To Financial Statements 26 Schedule E – Part 3 – Special Deposits	E28
	SI15
Overflow Page For Write-ins 44 Schedule S – Part 1 – Section 2	E29
	31
Schedule A – Part 1 E01 Schedule S – Part 2	32
Schedule A – Part 2 E02 Schedule S – Part 3 – Section 2	33
Schedule A – Part 3 E03 Schedule S – Part 4	34
Schedule A – Verification Between Years SI02 Schedule S – Part 5	35
Schedule B – Part 1 E04 Schedule S – Part 6	36
Schedule B – Part 2 E05 Schedule S – Part 7	37
Schedule B – Part 3 E06 Schedule T – Part 2 – Interstate Compact	: 39
Schedule B – Verification Between Years SI02 Schedule T – Premiums and Other Consideration	
Schedule BA – Part 1 E07 Schedule Y – Information Concerning Acti Holding Company Group	ivities of Insurer Members of a 40
Schedule BA – Part 2 E08 Schedule Y – Part 1A – Detail of Insurance	te Holding Company System 41
Schedule BA – Part 3 E09 Schedule Y – Part 2 – Summary of Insured Affiliates	er's Transactions With Any 42
Schedule BA – Verification Between Years SI03 Statement of Revenue and Expenses	4
Schedule D – Part 1 E10 Summary Investment Schedule	SI01
Schedule D – Part 1A – Section 1 SI05 Supplemental Exhibits and Schedules Inte	errogatories 43
Schedule D – Part 1A – Section 2 SI08 Underwriting and Investment Exhibit – Par	rt 1 8
Schedule D – Part 2 – Section 1 E11 Underwriting and Investment Exhibit – Part	rt 2 9
Schedule D – Part 2 – Section 2 E12 Underwriting and Investment Exhibit – Part	rt 2A 10
Schedule D – Part 3 E13 Underwriting and Investment Exhibit – Part	rt 2B 11
Schedule D – Part 4 E14 Underwriting and Investment Exhibit – Part	rt 2C 12
Schedule D – Part 5 E15 Underwriting and Investment Exhibit – Part	
Schedule D – Part 6 – Section 1 E16 Underwriting and Investment Exhibit – Part	rt 3 14
Schedule D – Part 6 – Section 2 E16	